

PATENT COOPERATION TREATY

PCT

NOTIFICATION OF ELECTION

(PCT Rule 61.2)

From the INTERNATIONAL BUREAU

To:

Commissioner
 US Department of Commerce
 United States Patent and Trademark
 Office, PCT
 2011 South Clark Place Room
 CP2/5C24
 Arlington, VA 22202
 ETATS-UNIS D'AMERIQUE
 in its capacity as elected Office

Date of mailing (day/month/year) 31 October 2000 (31.10.00)	
International application No. PCT/US00/04023	Applicant's or agent's file reference 4239-54105
International filing date (day/month/year) 16 February 2000 (16.02.00)	Priority date (day/month/year) 16 February 1999 (16.02.99)
Applicant LIOTTA, Lance, A. et al	

1. The designated Office is hereby notified of its election made:



in the demand filed with the International Preliminary Examining Authority on:

08 September 2000 (08.09.00)



in a notice effecting later election filed with the International Bureau on:

2. The election ☒ was

was not

made before the expiration of 19 months from the priority date or, where Rule 32 applies, within the time limit under Rule 32.2(b).

The International Bureau of WIPO 34, chemin des Colombettes 1211 Geneva 20, Switzerland Facsimile No.: (41-22) 740.14.35	Authorized officer F. Baechler Telephone No.: (41-22) 338.83.38
--	--

PATENT COOPERATION TREATY

PCT

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

(PCT Article 36 and Rule 70)

REC'D 15 MAY 2001

WIPO

PCT

14

Applicant's or agent's file reference 4239-54105	FOR FURTHER ACTION See Notification of Transmittal of International Preliminary Examination Report (Form PCT/IPEA/416)	
International application No. PCT/US00/04023	International filing date (day/month/year) 16/02/2000	Priority date (day/month/year) 16/02/1999
International Patent Classification (IPC) or national classification and IPC G01N33/68		
Applicant THE GOVERNMENT OF THE USA ... et al		

1. This international preliminary examination report has been prepared by this International Preliminary Examining Authority and is transmitted to the applicant according to Article 36.


2. This REPORT consists of a total of 9 sheets, including this cover sheet.

- ☐ This report is also accompanied by ANNEXES, i.e. sheets of the description, claims and/or drawings which have been amended and are the basis for this report and/or sheets containing rectifications made before this Authority (see Rule 70.16 and Section 607 of the Administrative Instructions under the PCT).

These annexes consist of a total of sheets.

3. This report contains indications relating to the following items:

- I ☒ Basis of the report
- II ☒ Priority
- III ☒ Non-establishment of opinion with regard to novelty, inventive step and industrial applicability
- IV ☒ Lack of unity of invention
- V ☒ Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement
- VI ☐ Certain documents cited
- VII ☒ Certain defects in the international application
- VIII ☒ Certain observations on the international application

Date of submission of the demand 08/09/2000	Date of completion of this report 10.05.2001
Name and mailing address of the international preliminary examining authority:  European Patent Office D-80298 Munich Tel. +49 89 2399 - 0 Tx: 523656 epmu d Fax: +49 89 2399 - 4465	Authorized officer Hoesel, H Telephone No. +49 89 2399 8693



INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No. PCT/US00/04023

I. Basis of the report

1. With regard to the **elements** of the international application (*Replacement sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to in this report as "originally filed" and are not annexed to this report since they do not contain amendments (Rules 70.16 and 70.17)*):

Description, pages:

1-42 as originally filed

Claims, No.:

1-40 as originally filed

Drawings, sheets:

1/22-22/22 as originally filed

2. With regard to the **language**, all the elements marked above were available or furnished to this Authority in the language in which the international application was filed, unless otherwise indicated under this item.

These elements were available or furnished to this Authority in the following language: , which is:

- ☐ the language of a translation furnished for the purposes of the international search (under Rule 23.1(b)).
- ☐ the language of publication of the international application (under Rule 48.3(b)).
- ☐ the language of a translation furnished for the purposes of international preliminary examination (under Rule 55.2 and/or 55.3).

3. With regard to any **nucleotide and/or amino acid sequence** disclosed in the international application, the international preliminary examination was carried out on the basis of the sequence listing:

- ☐ contained in the international application in written form.
- ☐ filed together with the international application in computer readable form.
- ☐ furnished subsequently to this Authority in written form.
- ☐ furnished subsequently to this Authority in computer readable form.
- ☐ The statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished.
- ☐ The statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished.

4. The amendments have resulted in the cancellation of:

- ☐ the description, pages:
- ☐ the claims, Nos.:

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No. PCT/US00/04023

☐ the drawings, sheets:

5. ☐ This report has been established as if (some of) the amendments had not been made, since they have been considered to go beyond the disclosure as filed (Rule 70.2(c)):

(Any replacement sheet containing such amendments must be referred to under item 1 and annexed to this report.)

6. Additional observations, if necessary:

II. Priority

1. ☐ This report has been established as if no priority had been claimed due to the failure to furnish within the prescribed time limit the requested:

☐ copy of the earlier application whose priority has been claimed.

☐ translation of the earlier application whose priority has been claimed.

2. ☒ This report has been established as if no priority had been claimed due to the fact that the priority claim has been found invalid.

Thus for the purposes of this report, the international filing date indicated above is considered to be the relevant date.

3. Additional observations, if necessary:
see separate sheet

III. Non-establishment of opinion with regard to novelty, inventive step and industrial applicability

1. The questions whether the claimed invention appears to be novel, to involve an inventive step (to be non-obvious), or to be industrially applicable have not been examined in respect of:

☐ the entire international application.

☒ claims Nos. 29 - 33.

because:

☐ the said international application, or the said claims Nos. relate to the following subject matter which does not require an international preliminary examination (*specify*):

☐ the description, claims or drawings (*indicate particular elements below*) or said claims Nos. are so unclear that no meaningful opinion could be formed (*specify*):

☐ the claims, or said claims Nos. are so inadequately supported by the description that no meaningful opinion

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No. PCT/US00/04023

could be formed.

☒ no international search report has been established for the said claims Nos. 29 - 33.

2. A meaningful international preliminary examination cannot be carried out due to the failure of the nucleotide and/or amino acid sequence listing to comply with the standard provided for in Annex C of the Administrative Instructions:

☐ the written form has not been furnished or does not comply with the standard.

☐ the computer readable form has not been furnished or does not comply with the standard.

IV. Lack of unity of invention

1. In response to the invitation to restrict or pay additional fees the applicant has:

☐ restricted the claims.

☐ paid additional fees.

☐ paid additional fees under protest.

☐ neither restricted nor paid additional fees.

2. ☒ This Authority found that the requirement of unity of invention is not complied and chose, according to Rule 68.1, not to invite the applicant to restrict or pay additional fees.

3. This Authority considers that the requirement of unity of invention in accordance with Rules 13.1, 13.2 and 13.3 is

☐ complied with.

☒ not complied with for the following reasons:
see separate sheet

4. Consequently, the following parts of the international application were the subject of international preliminary examination in establishing this report:

☒ all parts.

☐ the parts relating to claims Nos. .

V. Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

1. Statement

Novelty (N)

Yes: Claims 2 - 28, 36, 38

No: Claims 1, 34, 35, 37, 39, 40

Inventive step (IS)

Yes: Claims 9 - 11, 20, 21, 26 - 28

No: Claims 1 - 8, 12 - 19, 22 - 25, 34 - 40

**INTERNATIONAL PRELIMINARY
EXAMINATION REPORT**

International application No. PCT/US00/04023

Industrial applicability (IA) Yes: Claims 1 - 28, 34 - 40
 No: Claims

2. Citations and explanations
see separate sheet

VII. Certain defects in the international application

The following defects in the form or contents of the international application have been noted:
see separate sheet

VIII. Certain observations on the international application

The following observations on the clarity of the claims, description, and drawings or on the question whether the claims are fully supported by the description, are made:
see separate sheet

**INTERNATIONAL PRELIMINARY
EXAMINATION REPORT - SEPARATE SHEET**

International application No. PCT/US00/04023

Reference is made to the following documents:

D1: SIMONE N.L., ET AL: TRENDS IN GENETICS, vol. 14/7, 1998, p. 272-276,
D2: US-A-5 843 657

SECTION II:

1. The priority document does not provide support for the subject-matter of claims 34 - 40 insofar as cellular components other than proteins are concerned, or insofar as arrays are used in the analytical methods subsequent to laser capture microdissection ("LCM")

Thus, for such subject-matter of claims 34 - 40, the filing date is to be considered as the effective date for the assessment of novelty and inventive step.

SECTION IV:

2. The common link of the various independent process claims is the application of LCM, in order to obtain a homogenous cell sample, prior to analysis of cellular components. This common concept is anticipated by each of D1 and D2. D1 discloses the combination of LCM purification with subsequent analysis at the nucleic acid or the protein level (D1, fig 3); same does D2 (LCM followed by PCR or qualitative and quantitative zymography (D2, col. 7, line 55 - col. 8, line 34, examples 1 - 5).

The abovementioned feature does therefore not represent a common **inventive** link in the sense of Rule 13.2 PCT:

The application is therefore considered to contain the following separate groups of invention:

- (1) LCM followed by analysis of the total protein content (claims 1, 2, 15, 16, 25, 26)
- (2) LCM followed by immunological analysis of selected protein components (claims 4 - 8, 14, 18, 19; claims 34 to 40 in part),

(3) LCM combined with methods of sequence analysis of one or more proteins (claims 9 - 11, 20, 21, 26 - 28)

(4) LCM and analysis of cellular components other than proteins (claims 34 - 40, in part)

SECTION V:

- 3.1 D1 discloses LCM and in particular discloses its advantages over other methods of preparation of purified cell samples (D1, abstract). According to fig. 3, cell samples obtained by LCM can be subjected to molecular analyses at the nucleic acid level, such as DNA or RNA analyses by means of oligonucleotide/cDNA arrays.

Thus, D1 anticipates the methods as defined in claims of claims 34, 35, 37, 39 and 40 (Art. 33(2) PCT) and renders obvious the additional features given in claims 36 and 38 (Art. 33(3) PCT).

- 3.2. D2 concerns genetic analysis of LCM purified cellular samples, by means of PCR (Examples 2 - 5). In view of the feasibility of PCR analysis as shown in D2, a skilled person would consider the combination of this technology with hybridization of solid phase bound probes, e.g. oligonucleotide arrays as disclosed in D1 as obvious.

Thus, the subject-matter of claims 34 - 40 lacks an inventive step in view of D2 when read in conjunction with D1, contrary to Art. 33(3) PCT.

4. Having regard to p. 275, col. 1, lines 20 - 29, analyses of the protein content have been made. These tests revealed a linearity of the amount of protein per cell, or per spot captured. In addition, immunohistochemical staining and "soluble" immunoassays for single proteins have been performed (p. 275, col. 2, lines 1 - 4).

These assays essentially involve the steps as broadly outlined in claim 1.

Consequently, D1 is detrimental to the novelty of claim 1 (Art. 33(2) PCT).

**INTERNATIONAL PRELIMINARY
EXAMINATION REPORT - SEPARATE SHEET**

International application No. PCT/US00/04023

5. D1 explicitly suggests the application of this techniques in comparative testing (p. 276, col. 1, lines 20 - 29). It therefore renders obvious the subject-matter of claim 15, contrary to Art. 33(3) PCT.
6. Preliminary immunoassays mentioned in D1 ("immunohistochemical staining and soluble immunoassays") proved that the cellular proteins are immunologically preserved (fig. 3, and p. 275, col. 2, lines 1 - 4).

This teaching motivates a skilled person to analogously apply known immunocytochemical analyses to LCM purified samples. Thereby one would arrive at the method as defined in claims 4, 5, 8, 12, 13, 22 - 24 (Art. 33(3) PCT).

7. Claims 2, 3, 6 (step b), 7, 14, 16 - 19, 25 (step b), relate to (i) features that are commonly applied in immunocytochemical analyses, to (ii) the analysis of conventional tumour markers or (iii) to procedural modifications at which one arrives in the course of commonly applied laboratory routine procedures for optimization of analytical methods.

These features are therefore not considered to impart an inventive activity, contrary to Art. 33(3) PCT.

8. The relevant prior art does not disclose or suggest the combination of LCM purification with a sequence analysis of proteins or with protein fingerprinting.

Thus, the subject-matter of claims 9 - 11, 20, 21, 26 - 28, appears to meet the requirements of Art. 33(2) and (3) PCT.

SECTION VII:

9. Contrary to the requirements of Rule 5.1(a)(ii) PCT, the relevant background art disclosed in the document D1 is not mentioned in the description, nor is this document identified therein.

SECTION VIII:

**INTERNATIONAL PRELIMINARY
EXAMINATION REPORT - SEPARATE SHEET**

International application No. PCT/US00/04023

10. The vague and imprecise statement in the description on page 42, lines 18 - 20 implies that the subject-matter for which protection is sought may be different to that defined by the claims, thereby resulting in lack of clarity (Article 6 PCT) when used to interpret them (see also the PCT Guidelines, III-4.3a).

PATENT COOPERATION TREATY

From the INTERNATIONAL SEARCHING AUTHORITY

PCT

NOTIFICATION OF TRANSMITTAL OF
THE INTERNATIONAL SEARCH REPORT
OR THE DECLARATION

(PCT Rule 44.1)

To:

KLARQUIST, SPARKMAN, CAMPBELL,
LEIGH & WHINSTON, LLP
Attn. NOONAN, William
One World Trade Center, Suite 1600
121 S.W. Salmon Street
Portland, Oregon 97204
UNITED STATES OF AMERICA

Date of mailing
(day/month/year)

29/11/2000

Applicant's or agent's file reference

4239-54105

FOR FURTHER ACTION

See paragraphs 1 and 4 below

International application No.

PCT/US 00/ 04023

International filing date
(day/month/year)

16/02/2000

Applicant

THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as

1. ☒ The applicant is hereby notified that the International Search Report has been established and is transmitted herewith.

Filing of amendments and statement under Article 19:

The applicant is entitled, if he so wishes, to amend the claims of the International Application (see Rule 46):

When? The time limit for filing such amendments is normally 2 months from the date of transmittal of the International Search Report; however, for more details, see the notes on the accompanying sheet.

Where? Directly to the International Bureau of WIPO
34, chemin des Colombettes
1211 Geneva 20, Switzerland
Facsimile No.: (41-22) 740.14.35

For more detailed instructions, see the notes on the accompanying sheet.

2. ☐ The applicant is hereby notified that no International Search Report will be established and that the declaration under Article 17(2)(a) to that effect is transmitted herewith.

3. ☐ With regard to the protest against payment of (an) additional fee(s) under Rule 40.2, the applicant is notified that:

☐ the protest together with the decision thereon has been transmitted to the International Bureau together with the applicant's request to forward the texts of both the protest and the decision thereon to the designated Offices.

☐ no decision has been made yet on the protest; the applicant will be notified as soon as a decision is made.

4. **Further action(s):** The applicant is reminded of the following:

Shortly after **18 months** from the priority date, the international application will be published by the International Bureau. If the applicant wishes to avoid or postpone publication, a notice of withdrawal of the international application, or of the priority claim, must reach the International Bureau as provided in Rules 90bis.1 and 90bis.3, respectively, before the completion of the technical preparations for international publication.

Within **19 months** from the priority date, a demand for international preliminary examination must be filed if the applicant wishes to postpone the entry into the national phase until 30 months from the priority date (in some Offices even later).

Within **20 months** from the priority date, the applicant must perform the prescribed acts for entry into the national phase before all designated Offices which have not been elected in the demand or in a later election within 19 months from the priority date or could not be elected because they are not bound by Chapter II.

Name and mailing address of the International Searching Authority



European Patent Office, P.B. 5818 Patentlaan 2
NL-2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Jaap Hurenkamp

PCT

INTERNATIONAL SEARCH REPORT

(PCT Article 18 and Rules 43 and 44)

Applicant's or agent's file reference 4239-54105	FOR FURTHER ACTION see Notification of Transmittal of International Search Report (Form PCT/ISA/220) as well as, where applicable, item 5 below.	
International application No. PCT/US 00/ 04023	International filing date (day/month/year) 16/02/2000	(Earliest) Priority Date (day/month/year) 16/02/1999
Applicant THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as		

This International Search Report has been prepared by this International Searching Authority and is transmitted to the applicant according to Article 18. A copy is being transmitted to the International Bureau.

This International Search Report consists of a total of 4 sheets.

☒ It is also accompanied by a copy of each prior art document cited in this report.

1. Basis of the report

- a. With regard to the **language**, the international search was carried out on the basis of the international application in the language in which it was filed, unless otherwise indicated under this item.

☐ the international search was carried out on the basis of a translation of the international application furnished to this Authority (Rule 23.1(b)).

- b. With regard to any **nucleotide and/or amino acid sequence** disclosed in the international application, the international search was carried out on the basis of the sequence listing :

☐ contained in the international application in written form.

☐ filed together with the international application in computer readable form.

☐ furnished subsequently to this Authority in written form.

☐ furnished subsequently to this Authority in computer readable form.

☐ the statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished.

☐ the statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished

2. ☐ Certain claims were found unsearchable (See Box I).

3. ☐ Unity of invention is lacking (see Box II).

4. With regard to the **title**,

☐ the text is approved as submitted by the applicant.

☒ the text has been established by this Authority to read as follows:

LCM (LASER CAPTURE MICRODISSECTION) FOR CELLULAR PROTEIN ANALYSIS

5. With regard to the **abstract**,

☒ the text is approved as submitted by the applicant.

☐ the text has been established, according to Rule 38.2(b), by this Authority as it appears in Box III. The applicant may, within one month from the date of mailing of this international search report, submit comments to this Authority.

6. The figure of the **drawings** to be published with the abstract is Figure No.

☐ as suggested by the applicant.

☒ because the applicant failed to suggest a figure.

☐ because this figure better characterizes the invention.

2

☐ None of the figures.

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 00/04023

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 G01N33/68 G01N1/30 B01L3/00

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 G01N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EP0-Internal, WPI Data, BIOSIS

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	SIMONE N L ET AL: "Laser-capture microdissection: opening the microscopic frontier to molecular analysis" TRENDS IN GENETICS,NL,ELSEVIER SCIENCE PUBLISHERS B.V. AMSTERDAM, vol. 14, no. 7, 1 July 1998 (1998-07-01), pages 272-276, XP004124689 ISSN: 0168-9525 figures 2,3	1,8-10, 12,13, 15,17, 20-24
X	US 5 843 657 A (BUCK MICHAEL E ET AL) 1 December 1998 (1998-12-01) cited in the application examples 4,5 column 7, line 51 - line 54 -/--	1-5, 8-13,15, 17-24, 35-41

☒ Further documents are listed in the continuation of box C.☒ Patent family members are listed in annex.

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

28 July 2000

Date of mailing of the international search report

29. 11. 00

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Hart-Davis, J

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 00/04023

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P,X	BANKS ROSAMONDE E; DUNN MICHAEL J ET AL.: "The potential use of laser capture microdissection to selectively obtain distinct populations of cells for proteomic analysis - Preliminary findings" ELECTROPHORESIS, vol. 20, April 1999 (1999-04) - May 1999 (1999-05), pages 689-700, XP000925546 the whole document	1-5, 8-13,15, 17-24, 35-41
P,X	--- SIMONE N L; REMALEY A T; PETRICOIN E F; GLICKMAN J W; BONNER R; EMMERT-BUCK M R; FLEISCHER T A; LIOTTA L A: "PSA quantitation in prostate cancer tissue cells procured by laser capture microdissection" PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH ANNUAL MEETING (90TH ANNUAL MEETING, PHILADELPHIA, PENNSYLVANIA, USA; APRIL 10-14, 1999), vol. 40, March 1999 (1999-03), page 411 XP000929252 abstract	13,14
P,X	--- EMMERT-BUCK M R; ORNSTEIN D K; GILLESPIE J W; PAWELETZ C P; VOCKE C D; ET AL.: "Protein fingerprinting of LCM-dissected human esophageal and prostate cancer by 2D-PAGE" PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH ANNUAL MEETING (90TH ANNUAL MEETING, PHILADELPHIA, PENNSYLVANIA, USA; APRIL 10-14, 1999), vol. 40, no. 526, March 1999 (1999-03), page 526 XP000929253 abstract	13,14
T	--- EMMERT-BUCK MICHAEL R; GILLESPIE JOHN W ET AL.: "An approach to proteomic analysis of human tumors" MOLECULAR CARCINOGENESIS, vol. 27, March 2000 (2000-03), pages 158-165, XP000925515 the whole document --- -/--	1-29, 35-41

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 00/04023

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
T	CAZARES L H; GONG L; NASIM S; SCHELLMAMMER P F; WRIGHT G L JR: "Discovery of prostate cancer biomarkers from laser capture microdissected (LCM) cells using innovative ProteinChip™ SELDI mass spectroscopy" PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH ANNUAL MEETING (91ST ANNUAL MEETING, SAN FRANCISCO, CALIFORNIA, USA; APRIL 01-05, 2000), March 2000 (2000-03), page 851 XP000929268 abstract ---	13,14
A	US 4 976 957 A (BOGOCH SAMUEL) 11 December 1990 (1990-12-11) examples 1-5 ---	
A	DATABASE WPI Week 198703 Derwent Publications Ltd., London, GB; AN 1987-017788 XP002143852 NOGUCHI JUJI ET AL.: "Protein from animal cerebral nerve tumour cell ..." & JP 61 275221 A (MITSUI PHARMACEUT. INC.) , 5 December 1986 (1986-12-05) abstract -----	

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 00/04023

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US 5843657 A	01-12-1998	US 5843644 A	01-12-1998
		AU 716979 B	16-03-2000
		AU 7663396 A	30-04-1997
		CA 2233614 A	17-04-1997
		EP 0862612 A	09-09-1998
		JP 2000500325 T	18-01-2000
		WO 9713838 A	17-04-1997
		US 6010888 A	04-01-2000
		AT 182405 T	15-08-1999
		AU 691263 B	14-05-1998
		AU 1933795 A	18-09-1995
		CA 2184245 A	08-09-1995
		CN 1143413 A	19-02-1997
		DE 69510925 D	26-08-1999
		DE 69510925 T	17-02-2000
		EP 0748439 A	18-12-1996
		ES 2138727 T	16-01-2000
		JP 10500205 T	06-01-1998
		WO 9523960 A	08-09-1995

US 4976957 A	11-12-1990	US 4298590 A	03-11-1981
		US 4840915 A	20-06-1989
		AT 8897 T	15-08-1984
		DE 3068844 D	13-09-1984
		EP 0015755 A	17-09-1980
		JP 1514082 C	24-08-1989
		JP 55167265 A	26-12-1980
		JP 63062517 B	02-12-1988
		CA 1057684 A	03-07-1979
		CH 639102 A	31-10-1983
		DE 2606257 A	26-08-1976
		FR 2327798 A	13-05-1977
		GB 1533464 A	22-11-1978
		JP 1046520 B	09-10-1989
		JP 1565629 C	25-06-1990
		JP 51108001 A	25-09-1976
		JP 1112163 A	28-04-1989
		JP 1633581 C	20-01-1992
		JP 2057671 B	05-12-1990
		US 4195017 A	25-03-1980
		US 4196186 A	01-04-1980
		AT 16220 T	15-11-1985
		DE 2967534 D	28-11-1985
		EP 0007214 A	23-01-1980
		HU 185603 B	28-03-1985
		JP 55037989 A	17-03-1980
		US 4486538 A	04-12-1984

JP 61275221 A	05-12-1986	NONE	

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US 00/04023

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

see additional sheet

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☒ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:
1-29, 35-41

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
☐ No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. Claims: 1-29,35-41

Methods of analysing proteins or other cellular components involving the extraction of a population of cells from a tissue sample using laser capture microdissection.

2. Claims: 30-34

Devices comprising chambers having at least one input port.

From the INTERNATIONAL SEARCHING AUTHORITY

PCT

NOTIFICATION OF TRANSMITTAL OF
THE INTERNATIONAL SEARCH REPORT
OR THE DECLARATION

(PCT Rule 44.1)

To:
KLARQUIST, SPARKMAN, CAMPBELL,
LEIGH & WHINSTON, LLP
Attn. NOONAN, William
One World Trade Center, Suite 1600
121 S.W. Salmon Street
Portland, Oregon 97204
UNITED STATES OF AMERICA

Date of mailing
(day/month/year) 29/11/2000

Applicant's or agent's file reference
4239-54105

FOR FURTHER ACTION See paragraphs 1 and 4 below

International application No.
PCT/US 00/04023

International filing date
(day/month/year) 16/02/2000

Applicant

THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as

DOCKETED FOR: 1-29-01
7-28-01
COMPUTER
CARD

1. ☒ The applicant is hereby notified that the International Search Report has been established and is transmitted herewith.

Filing of amendments and statement under Article 19:

The applicant is entitled, if he so wishes, to amend the claims of the International Application (see Rule 46):

When? The time limit for filing such amendments is normally 2 months from the date of transmittal of the International Search Report; however, for more details, see the notes on the accompanying sheet.

Where? Directly to the International Bureau of WIPO
34, chemin des Colombettes
1211 Geneva 20, Switzerland
Facsimile No.: (41-22) 740.14.35

For more detailed instructions, see the notes on the accompanying sheet.

2. ☐ The applicant is hereby notified that no International Search Report will be established and that the declaration under Article 17(2)(a) to that effect is transmitted herewith.

3. ☐ With regard to the protest against payment of (an) additional fee(s) under Rule 40.2, the applicant is notified that:

☐ the protest together with the decision thereon has been transmitted to the International Bureau together with the applicant's request to forward the texts of both the protest and the decision thereon to the designated Offices.

☐ no decision has been made yet on the protest; the applicant will be notified as soon as a decision is made.

4. **Further action(s):** The applicant is reminded of the following:

Shortly after 18 months from the priority date, the international application will be published by the International Bureau. If the applicant wishes to avoid or postpone publication, a notice of withdrawal of the international application, or of the priority claim, must reach the International Bureau as provided in Rules 90bis.1 and 90bis.3, respectively, before the completion of the technical preparations for international publication.

Within 19 months from the priority date, a demand for international preliminary examination must be filed if the applicant wishes to postpone the entry into the national phase until 30 months from the priority date (in some Offices even later).

Within 20 months from the priority date, the applicant must perform the prescribed acts for entry into the national phase before all designated Offices which have not been elected in the demand or in a later election within 19 months from the priority date or could not be elected because they are not bound by Chapter II.

Name and mailing address of the International Searching Authority



European Patent Office, P.B. 5818 Patentlaan 2
NL-2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Jaap Hurenkamp

PCT

INTERNATIONAL SEARCH REPORT

(PCT Article 18 and Rules 43 and 44)

Applicant's or agent's file reference 4239-54105	FOR FURTHER ACTION see Notification of Transmittal of International Search Report (Form PCT/ISA/220) as well as, where applicable, item 5 below.	
International application No. PCT/US 00/ 04023	International filing date (day/month/year) 16/02/2000	(Earliest) Priority Date (day/month/year) 16/02/1999
Applicant THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as		

This International Search Report has been prepared by this International Searching Authority and is transmitted to the applicant according to Article 18. A copy is being transmitted to the International Bureau.

This International Search Report consists of a total of 4 sheets.

☒ It is also accompanied by a copy of each prior art document cited in this report.

1. Basis of the report

- a. With regard to the **language**, the international search was carried out on the basis of the international application in the language in which it was filed, unless otherwise indicated under this item.

☐ the international search was carried out on the basis of a translation of the international application furnished to this Authority (Rule 23.1(b)).

- b. With regard to any **nucleotide and/or amino acid sequence** disclosed in the international application, the international search was carried out on the basis of the sequence listing :

☐ contained in the international application in written form.

☐ filed together with the international application in computer readable form.

☐ furnished subsequently to this Authority in written form.

☐ furnished subsequently to this Authority in computer readable form.

☐ the statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished.

☐ the statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished

2. ☐ **Certain claims were found unsearchable** (See Box I).

3. ☐ **Unity of invention is lacking** (see Box II).

4. With regard to the **title**,

☐ the text is approved as submitted by the applicant.

☒ the text has been established by this Authority to read as follows:

LCM (LASER CAPTURE MICRODISSECTION) FOR CELLULAR PROTEIN ANALYSIS

5. With regard to the **abstract**,

☒ the text is approved as submitted by the applicant.

☐ the text has been established, according to Rule 38.2(b), by this Authority as it appears in Box III. The applicant may, within one month from the date of mailing of this international search report, submit comments to this Authority.

6. The figure of the **drawings** to be published with the abstract is Figure No.

☐ as suggested by the applicant.

☒ because the applicant failed to suggest a figure.

☐ because this figure better characterizes the invention.

2
☐ None of the figures.

INTERNATIONAL SEARCH REPORT

National Application No

CT/US 00/04023

A. CLASSIFICATION OF SUBJECT MATTER
 IPC 7 G01N33/68 G01N1/30 B01L3/00

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 G01N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, BIOSIS

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	SIMONE N L ET AL: "Laser-capture microdissection: opening the microscopic frontier to molecular analysis" TRENDS IN GENETICS,NL,ELSEVIER SCIENCE PUBLISHERS B.V. AMSTERDAM, vol. 14, no. 7, 1 July 1998 (1998-07-01), pages 272-276, XP004124689 ISSN: 0168-9525 figures 2,3	1,8-10, 12,13, 15,17, 20-24
X	US 5 843 657 A (BUCK MICHAEL E ET AL) 1 December 1998 (1998-12-01) cited in the application examples 4,5 column 7, line 51 - line 54 --- -/--	1-5, 8-13,15, 17-24, 35-41

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

28 July 2000

Date of mailing of the international search report

29. 11. 00

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
 NL - 2280 HV Rijswijk
 Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
 Fax: (+31-70) 340-3016

Authorized officer

Hart-Davis, J

INTERNATIONAL SEARCH REPORT

International Application No

CT/US 00/04023

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P,X	BANKS ROSAMONDE E; DUNN MICHAEL J ET AL.: "The potential use of laser capture microdissection to selectively obtain distinct populations of cells for proteomic analysis - Preliminary findings" ELECTROPHORESIS, vol. 20, April 1999 (1999-04) - May 1999 (1999-05), pages 689-700, XP000925546 the whole document	1-5, 8-13,15, 17-24, 35-41
P,X	--- SIMONE N L; REMALEY A T; PETRICOIN E F; GLICKMAN J W; BONNER R; EMMERT-BUCK M R; FLEISCHER T A; LIOTTA L A: "PSA quantitation in prostate cancer tissue cells procured by laser capture microdissection" PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH ANNUAL MEETING (90TH ANNUAL MEETING, PHILADELPHIA, PENNSYLVANIA, USA; APRIL 10-14, 1999), vol. 40, March 1999 (1999-03), page 411 XP000929252 abstract	13,14
P,X	--- EMMERT-BUCK M R; ORNSTEIN D K; GILLESPIE J W; PAWELETZ C P; VOCKE C D; ET AL.: "Protein fingerprinting of LCM-dissected human esophageal and prostate cancer by 2D-PAGE" PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH ANNUAL MEETING (90TH ANNUAL MEETING, PHILADELPHIA, PENNSYLVANIA, USA; APRIL 10-14, 1999), vol. 40, no. 526, March 1999 (1999-03), page 526 XP000929253 abstract	13,14
T	--- EMMERT-BUCK MICHAEL R; GILLESPIE JOHN W ET AL.: "An approach to proteomic analysis of human tumors" MOLECULAR CARCINOGENESIS, vol. 27, March 2000 (2000-03), pages 158-165, XP000925515 the whole document --- -/--	1-29, 35-41

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 00/04023

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
T	CAZARES L H; GONG L; NASIM S; SCHELLMAMMER P F; WRIGHT G L JR: "Discovery of prostate cancer biomarkers from laser capture microdissected (LCM) cells using innovative ProteinChip™ SELDI mass spectroscopy" PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH ANNUAL MEETING (91ST ANNUAL MEETING, SAN FRANCISCO, CALIFORNIA, USA; APRIL 01-05, 2000), March 2000 (2000-03), page 851 XP000929268 abstract ---	13,14
A	US 4 976 957 A (BOGOCH SAMUEL) 11 December 1990 (1990-12-11) examples 1-5 ---	
A	DATABASE WPI Week 198703 Derwent Publications Ltd., London, GB; AN 1987-017788 XP002143852 NOGUCHI JUJI ET AL.: "Protein from animal cerebral nerve tumour cell ..." & JP 61 275221 A (MITSUI PHARMACEUT. INC.) , 5 December 1986 (1986-12-05) abstract -----	

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 00/04023

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US 5843657 A	01-12-1998	US 5843644 A	01-12-1998
		AU 716979 B	16-03-2000
		AU 7663396 A	30-04-1997
		CA 2233614 A	17-04-1997
		EP 0862612 A	09-09-1998
		JP 2000500325 T	18-01-2000
		WO 9713838 A	17-04-1997
		US 6010888 A	04-01-2000
		AT 182405 T	15-08-1999
		AU 691263 B	14-05-1998
		AU 1933795 A	18-09-1995
		CA 2184245 A	08-09-1995
		CN 1143413 A	19-02-1997
		DE 69510925 D	26-08-1999
		DE 69510925 T	17-02-2000
		EP 0748439 A	18-12-1996
		ES 2138727 T	16-01-2000
		JP 10500205 T	06-01-1998
		WO 9523960 A	08-09-1995
-----	-----	-----	-----
US 4976957 A	11-12-1990	US 4298590 A	03-11-1981
		US 4840915 A	20-06-1989
		AT 8897 T	15-08-1984
		DE 3068844 D	13-09-1984
		EP 0015755 A	17-09-1980
		JP 1514082 C	24-08-1989
		JP 55167265 A	26-12-1980
		JP 63062517 B	02-12-1988
		CA 1057684 A	03-07-1979
		CH 639102 A	31-10-1983
		DE 2606257 A	26-08-1976
		FR 2327798 A	13-05-1977
		GB 1533464 A	22-11-1978
		JP 1046520 B	09-10-1989
		JP 1565629 C	25-06-1990
		JP 51108001 A	25-09-1976
		JP 1112163 A	28-04-1989
		JP 1633581 C	20-01-1992
		JP 2057671 B	05-12-1990
		US 4195017 A	25-03-1980
		US 4196186 A	01-04-1980
		AT 16220 T	15-11-1985
		DE 2967534 D	28-11-1985
		EP 0007214 A	23-01-1980
		HU 185603 B	28-03-1985
		JP 55037989 A	17-03-1980
		US 4486538 A	04-12-1984
-----	-----	-----	-----
JP 61275221 A	05-12-1986	NONE	
-----	-----	-----	-----

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US 00/04023

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

see additional sheet

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☒ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

1-29, 35-41

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. Claims: 1-29,35-41

Methods of analysing proteins or other cellular components involving the extraction of a population of cells from a tissue sample using laser capture microdissection.

2. Claims: 30-34

Devices comprising chambers having at least one input port.

From the:
INTERNATIONAL PRELIMINARY EXAMINING AUTHORITY

To:

NOONAN, William
KLARQUIST, SPARKMAN, CAMPBELL,
LEIGH & WHINSTON, LLP
One World Trade Center, Suite 1600
121 S.W. Salmon Street
Portland, Oregon 97204
ETATS-UNIS D'AMERIQUE

PCT

WRITTEN OPINION

(PCT Rule 66)

Date of mailing (day/month/year)	04.01.2001
-------------------------------------	------------

Applicant's or agent's file reference 4239-54105	REPLY DUE within 3 month(s) from the above date of mailing
---	--

International application No. PCT/US00/04023	International filing date (day/month/year) 16/02/2000	Priority date (day/month/year) 16/02/1999
---	--	--

International Patent Classification (IPC) or both national classification and IPC G01N33/68
--

Applicant THE GOVERNMENT OF THE USA ... et al
--

1. This written opinion is the **first** drawn up by this International Preliminary Examining Authority.

2. This opinion contains indications relating to the following items:

- I ☒ Basis of the opinion
- II ☒ Priority
- III ☒ Non-establishment of opinion with regard to novelty, inventive step and industrial applicability
- IV ☒ Lack of unity of invention
- V ☒ Reasoned statement under Rule 66.2(a)(ii) with regard to novelty, inventive step or industrial applicability, citations and explanations supporting such statement
- VI ☐ Certain document cited
- VII ☒ Certain defects in the international application
- VIII ☒ Certain observations on the international application

DOCKETED FOR: 4/4/01

COMPUTER ☒

CARD ☐

BOOK ☐

DRAWER ☐

BNPR ☐

3. The applicant is hereby **invited to reply** to this opinion.

When? See the time limit indicated above. The applicant may, before the expiration of that time limit request this Authority to grant an extension, see Rule 66.2(d).

How? By submitting a written reply, accompanied, where appropriate, by amendments, according to Rule 66.3. For the form and the language of the amendments, see Rules 66.8 and 66.9.

Also: For an additional opportunity to submit amendments, see Rule 66.4.
For the examiner's obligation to consider amendments and/or arguments, see Rule 66.4 bis.
For an informal communication with the examiner, see Rule 66.6.

If no reply is filed, the international preliminary examination report will be established on the basis of this opinion.

4. The final date by which the international preliminary examination report must be established according to Rule 69.2 is: 16/06/2001.

Name and mailing address of the international preliminary examining authority:	Authorized officer / Examiner
--	-------------------------------



European Patent Office
D-80298 Munich
Tel. +49 89 2399 - 0 Tx: 523656 epmu d
Fax: +49 89 2399 - 4465

Hoesel, H

Formalities officer (incl. extension of time limits)
Pedersen, C
Telephone No. +49 89 2399 8063



I. Basis of the opinion

1. This opinion has been drawn on the basis of (*substitute sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to in this opinion as "originally filed".*):

Description, pages:

1-42 as originally filed

Claims, No.:

1-24,26-41 as originally filed

Drawings, sheets:

1/22-22/22 as originally filed

2. With regard to the **language**, all the elements marked above were available or furnished to this Authority in the language in which the international application was filed, unless otherwise indicated under this item.

These elements were available or furnished to this Authority in the following language: , which is:

- ☐ the language of a translation furnished for the purposes of the international search (under Rule 23.1(b)).
- ☐ the language of publication of the international application (under Rule 48.3(b)).
- ☐ the language of a translation furnished for the purposes of international preliminary examination (under Rule 55.2 and/or 55.3).

3. With regard to any **nucleotide and/or amino acid sequence** disclosed in the international application, the international preliminary examination was carried out on the basis of the sequence listing:

- ☐ contained in the international application in written form.
- ☐ filed together with the international application in computer readable form.
- ☐ furnished subsequently to this Authority in written form.
- ☐ furnished subsequently to this Authority in computer readable form.
- ☐ The statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished.
- ☐ The statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished.

4. The amendments have resulted in the cancellation of:

- ☐ the description, pages:
- ☐ the claims, Nos.:

WRITTEN OPINION

International application No. PCT/US00/04023

☐ the drawings, sheets:

5. ☐ This report has been established as if (some of) the amendments had not been made, since they have been considered to go beyond the disclosure as filed (Rule 70.2(c)):

(Any replacement sheet containing such amendments must be referred to under item 1 and annexed to this report.)

6. Additional observations, if necessary:

II. Priority

1. ☐ This opinion has been established as if no priority had been claimed due to the failure to furnish within the prescribed time limit the requested:

☐ copy of the earlier application whose priority has been claimed.

☐ translation of the earlier application whose priority has been claimed.

2. ☒ This opinion has been established as if no priority had been claimed due to the fact that the priority claim has been found invalid.

Thus for the purposes of this opinion, the international filing date indicated above is considered to be the relevant date.

3. Additional observations, if necessary:

see separate sheet

III. Non-establishment of opinion with regard to novelty, inventive step and industrial applicability

1. The questions whether the claimed invention appears to be novel, to involve an inventive step (to be non-obvious), or to be industrially applicable have not been and will not be examined in respect of:

☐ the entire international application,

☒ claims Nos. 30 - 34,

because:

☐ the said international application, or the said claims Nos. relate to the following subject matter which does not require an international preliminary examination (*specify*):

☐ the description, claims or drawings (*indicate particular elements below*) or said claims Nos. are so unclear that no meaningful opinion could be formed (*specify*):

☐ the claims, or said claims Nos. are so inadequately supported by the description that no meaningful opinion

could be formed.

☒ no international search report has been established for the said claims Nos. 30 - 34.

2. A written opinion cannot be drawn due to the failure of the nucleotide and/or amino acid sequence listing to comply with the standard provided for in Annex C of the Administrative Instructions:

☐ the written form has not been furnished or does not comply with the standard.

☐ the computer readable form has not been furnished or does not comply with the standard.

IV. Lack of unity of invention

1. In response to the invitation (Form PCT/IPEA/405) to restrict or pay additional fees, the applicant has:

☐ restricted the claims.

☐ paid additional fees.

☐ paid additional fees under protest.

☐ neither restricted nor paid additional fees.

2. ☒ This Authority found that the requirement of unity of invention is not complied with for the following reasons and chose, according to Rule 68.1, not to invite the applicant to restrict or pay additional fees:
see separate sheet

3. Consequently, the following parts of the international application were the subject of international preliminary examination in establishing this opinion:

☒ all parts.

☐ the parts relating to claims Nos. .

V. Reasoned statement under Rule 66.2(a)(ii) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

1. Statement

Novelty (N)	Claims	1, 35, 36, 38, 40, 41 (no)
Inventive step (IS)	Claims	1 - 8, 12 - 19, 22 - 24, 35 - 41 (no)
Industrial applicability (IA)	Claims	1 - 24, 26 - 29, 35 - 41 (yes)

2. Citations and explanations
see separate sheet

VII. Certain defects in the international application

The following defects in the form or contents of the international application have been noted:
see separate sheet

VIII. Certain observations on the international application

The following observations on the clarity of the claims, description, and drawings or on the question whether the claims are fully supported by the description, are made:
see separate sheet

Reference is made to the following documents:

D1: SIMONE N.L., ET AL: TRENDS IN GENETICS, vol. 14/7, 1998, p. 272-276,
D2: US-A-5 843 657

SECTION II:

1. The priority document does not provide support for the subject-matter of claims 35 - 41 insofar as cellular components other proteins are concerned, or insofar as arrays are involved in the analytical methods subsequent to laser capture microdissection ("LCM")

Thus, for the subject-matter of claims 35 - 41 the filing date is to be considered as the effective date for the assessment of novelty and inventive step.

SECTION IV:

2. The common link of the various independent process claims is the application of LCM, in order to obtain a homogenous cell sample, prior to analysis of cellular components. This common concept is anticipated by each of D1 and D2 D1 discloses the combination of LCM purification with subsequent analysis at the nucleic acid or the protein level (D1, fig 3); same does D2 (LCM followed by PCR or qualitative and quantitative zymography (D2, col. 7, line 55 - col. 8, line 34, examples 1 - 5).

The said feature does not therefore represent a common **inventive** link in the sense of Rule 13.2 PCT.

The application is therefore considered to contain the following separate groups of invention:

- (1) LCM followed by analysis of the total protein content (claims 1, 2, 15, 16, 26, 27)
- (2) LCM followed by immunological analysis of selected protein components (claims 4 - 8, 14, 18, 19; claims 35 to 41 in part),

(3) LCM combined with methods of sequence analysis of one or more proteins (claims 9 - 11, 20, 21, 27 - 29)

(4) LCM and analysis of cellular components other than proteins (claims 35 - 41, in part)

SECTION V:

- 3.1 D1 discloses LCM and in particular discloses its advantages over other methods of preparation of purified cell samples (D1, abstract). According to fig 3, cell samples obtained by LCM can be subjected to molecular analyses at the nucleic acid level, such as DNA or RNA analyses by means of oligonucleotide/cDNA arrays.

Thus, D1 anticipates the methods as defined in claims 35, 36, 38, 40 and 41 (Art. 33(2) PCT) and renders obvious the additional features given in claims 37 and 39 (Art. 33(3) PCT).

- 3.2. D2 concerns genetic analysis of LCM purified cellular samples, by means of PCR (Examples 2 - 5). In view of the feasibility of PCR analysis as shown in D2, a skilled person would consider the combination of this technology with hybridization of solid phase bound probes, e.g. oligonucleotide arrays as disclosed in D1 as obvious.

Thus, the subject-matter of claims 35 - 41 lacks an inventive step in view of D2 when read in conjunction with D1, contrary to Art. 33(3) PCT.

4. Having regard to p. 275, col. 1, lines 20 - 29, analyses of the protein content have been made. These tests revealed a linearity of the amount of protein per cell, or per spot captured. In addition, soluble immunoassay of single proteins have been performed (p. 275, col. 2, lines 1 - 4).

These assays essentially involve the steps as broadly outlined in claim 1.

Consequently D1 is detrimental to the novelty of claim 1, contrary to Art. 33(2) PCT.

5. D1 explicitly mentions the application of this techniques in comparative testing (p. 276, col. 1, lines 20 - 29), and thereby renders the subject-matter of claim 15 obvious, contrary to Art. 33(3) PCT.
6. Preliminary immunoassays mentioned in D1 ("immunohistochemical staining and soluble immunoassays") proved that the cellular proteins are immunologically preserved (fig. 3, and p. 275, col. 2, lines 1 - 4).

This teaching motivates a skilled person to analogously apply known immunocyto-chemical analyses to LCM purified samples. Thereby one would arrive at the method as defined in claims 4, 5, 8, 12, 13, 22 - 24 (Art. 33(3) PCT).

7. Claims 2, 3, 6 (step b), 7, 14, 16 - 19, 26 (step b), relate to features that are commonly applied in immunocytochemical analyses, to the analysis of conventional tumour markers or to procedural modifications at which one arrives in the course of commonly applied laboratory routine procedures for optimization of analytical methods.

These features are therefore not considered to impart an inventive activity, contrary to Art. 33(3) PCT.

8. The relevant prior art does not disclose or suggest the combination of LCM purification with a sequence analysis of proteins or with protein fingerprinting.

Thus, the subject-matter of claims 9 - 11, 20, 21, 27 - 29, appears to meet the requirements of Art. 33(2) and (3) PCT.

SECTION VII:

9. Contrary to the requirements of Rule 5.1(a)(ii) PCT, the relevant background art disclosed in the document D1 is not mentioned in the description, nor is this document identified therein.
10. The claims are not consecutively numbered (claim 25 missing), contrary to Rule 6.1(b) PCT.



SECTION VIII:

11. The vague and imprecise statement in the description on page 42, lines 18 - 20 implies that the subject-matter for which protection is sought may be different to that defined by the claims, thereby resulting in lack of clarity (Article 6 PCT) when used to interpret them (see also the PCT Guidelines, III-4.3a).

PCT

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

(PCT Article 36 and Rule 70)

Applicant's or agent's file reference 4239-54105		FOR FURTHER ACTION	See Notification of Transmittal of International Preliminary Examination Report (Form PCT/IPEA/416)
International application No. PCT/US00/04023	International filing date (day/month/year) 16/02/2000	Priority date (day/month/year) 16/02/1999	
International Patent Classification (IPC) or national classification and IPC G01N33/68			
Applicant THE GOVERNMENT OF THE USA ... et al			
<p>1. This international preliminary examination report has been prepared by this International Preliminary Examining Authority and is transmitted to the applicant according to Article 36.</p> <p>2. This REPORT consists of a total of 9 sheets, including this cover sheet.</p> <p><input type="checkbox"/> This report is also accompanied by ANNEXES, i.e. sheets of the description, claims and/or drawings which have been amended and are the basis for this report and/or sheets containing rectifications made before this Authority (see Rule 70.16 and Section 607 of the Administrative Instructions under the PCT).</p> <p>These annexes consist of a total of sheets.</p>			
<p>3. This report contains indications relating to the following items:</p> <ul style="list-style-type: none"> I <input checked="" type="checkbox"/> Basis of the report II <input checked="" type="checkbox"/> Priority III <input checked="" type="checkbox"/> Non-establishment of opinion with regard to novelty, inventive step and industrial applicability IV <input checked="" type="checkbox"/> Lack of unity of invention V <input checked="" type="checkbox"/> Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement VI <input type="checkbox"/> Certain documents cited VII <input checked="" type="checkbox"/> Certain defects in the international application VIII <input checked="" type="checkbox"/> Certain observations on the international application 			
Date of submission of the demand 08/09/2000		Date of completion of this report 10.05.2001	
Name and mailing address of the international preliminary examining authority:  European Patent Office D-80298 Munich Tel. +49 89 2399 - 0 Tx: 523656 epmu d Fax: +49 89 2399 - 4465		Authorized officer Hoesel, H Telephone No. +49 89 2399 8693 	

**INTERNATIONAL PRELIMINARY
EXAMINATION REPORT**

International application No. PCT/US00/04023

I. Basis of the report

1. With regard to the **elements** of the international application (*Replacement sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to in this report as "originally filed" and are not annexed to this report since they do not contain amendments (Rules 70.16 and 70.17)*):

Description, pages:

1-42 as originally filed

Claims, No.:

1-40 as originally filed

Drawings, sheets:

1/22-22/22 as originally filed

2. With regard to the **language**, all the elements marked above were available or furnished to this Authority in the language in which the international application was filed, unless otherwise indicated under this item.

These elements were available or furnished to this Authority in the following language: , which is:

- ☐ the language of a translation furnished for the purposes of the international search (under Rule 23.1(b)).
- ☐ the language of publication of the international application (under Rule 48.3(b)).
- ☐ the language of a translation furnished for the purposes of international preliminary examination (under Rule 55.2 and/or 55.3).

3. With regard to any **nucleotide and/or amino acid sequence** disclosed in the international application, the international preliminary examination was carried out on the basis of the sequence listing:

- ☐ contained in the international application in written form.
- ☐ filed together with the international application in computer readable form.
- ☐ furnished subsequently to this Authority in written form.
- ☐ furnished subsequently to this Authority in computer readable form.
- ☐ The statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished.
- ☐ The statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished.

4. The amendments have resulted in the cancellation of:

- ☐ the description, pages:
- ☐ the claims, Nos.:

**INTERNATIONAL PRELIMINARY
EXAMINATION REPORT**

International application No. PCT/US00/04023

☐ the drawings, sheets:

5. ☐ This report has been established as if (some of) the amendments had not been made, since they have been considered to go beyond the disclosure as filed (Rule 70.2(c)):

(Any replacement sheet containing such amendments must be referred to under item 1 and annexed to this report.)

6. Additional observations, if necessary:

II. Priority

1. ☐ This report has been established as if no priority had been claimed due to the failure to furnish within the prescribed time limit the requested:

☐ copy of the earlier application whose priority has been claimed.

☐ translation of the earlier application whose priority has been claimed.

2. ☒ This report has been established as if no priority had been claimed due to the fact that the priority claim has been found invalid.

Thus for the purposes of this report, the international filing date indicated above is considered to be the relevant date.

3. Additional observations, if necessary:
see separate sheet

III. Non-establishment of opinion with regard to novelty, inventive step and industrial applicability

1. The questions whether the claimed invention appears to be novel, to involve an inventive step (to be non-obvious), or to be industrially applicable have not been examined in respect of:

☐ the entire international application.

☒ claims Nos. 29 - 33.

because:

☐ the said international application, or the said claims Nos. relate to the following subject matter which does not require an international preliminary examination (*specify*):

☐ the description, claims or drawings (*indicate particular elements below*) or said claims Nos. are so unclear that no meaningful opinion could be formed (*specify*):

☐ the claims, or said claims Nos. are so inadequately supported by the description that no meaningful opinion

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No. PCT/US00/04023

could be formed.

☒ no international search report has been established for the said claims Nos. 29 - 33.

2. A meaningful international preliminary examination cannot be carried out due to the failure of the nucleotide and/or amino acid sequence listing to comply with the standard provided for in Annex C of the Administrative Instructions:

☐ the written form has not been furnished or does not comply with the standard.

☐ the computer readable form has not been furnished or does not comply with the standard.

IV. Lack of unity of invention

1. In response to the invitation to restrict or pay additional fees the applicant has:

☐ restricted the claims.

☐ paid additional fees.

☐ paid additional fees under protest.

☐ neither restricted nor paid additional fees.

2. ☒ This Authority found that the requirement of unity of invention is not complied and chose, according to Rule 68.1, not to invite the applicant to restrict or pay additional fees.

3. This Authority considers that the requirement of unity of invention in accordance with Rules 13.1, 13.2 and 13.3 is

☐ complied with.

☒ not complied with for the following reasons:
see separate sheet

4. Consequently, the following parts of the international application were the subject of international preliminary examination in establishing this report:

☒ all parts.

☐ the parts relating to claims Nos. .

V. Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

1. Statement

Novelty (N)	Yes: Claims 2 - 28, 36, 38
	No: Claims 1, 34, 35, 37, 39, 40

Inventive step (IS)	Yes: Claims 9 - 11, 20, 21, 26 - 28
	No: Claims 1 - 8, 12 - 19, 22 - 25, 34 - 40

**INTERNATIONAL PRELIMINARY
EXAMINATION REPORT**

International application No. PCT/US00/04023

Industrial applicability (IA) Yes: Claims 1 - 28, 34 - 40
 No: Claims

2. Citations and explanations
see separate sheet

VII. Certain defects in the international application

The following defects in the form or contents of the international application have been noted:
see separate sheet

VIII. Certain observations on the international application

The following observations on the clarity of the claims, description, and drawings or on the question whether the claims are fully supported by the description, are made:
see separate sheet

**INTERNATIONAL PRELIMINARY
EXAMINATION REPORT - SEPARATE SHEET**

International application No. PCT/US00/04023

Reference is made to the following documents:

D1: SIMONE N.L., ET AL: TRENDS IN GENETICS, vol. 14/7, 1998, p. 272-276,
D2: US-A-5 843 657

SECTION II:

1. The priority document does not provide support for the subject-matter of claims 34 - 40 insofar as cellular components other than proteins are concerned, or insofar as arrays are used in the analytical methods subsequent to laser capture microdissection ("LCM")

Thus, for such subject-matter of claims 34 - 40, the filing date is to be considered as the effective date for the assessment of novelty and inventive step.

SECTION IV:

2. The common link of the various independent process claims is the application of LCM, in order to obtain a homogenous cell sample, prior to analysis of cellular components. This common concept is anticipated by each of D1 and D2. D1 discloses the combination of LCM purification with subsequent analysis at the nucleic acid or the protein level (D1, fig 3); same does D2 (LCM followed by PCR or qualitative and quantitative zymography (D2, col. 7, line 55 - col. 8, line 34, examples 1 - 5).

The abovementioned feature does therefore not represent a common **inventive** link in the sense of Rule 13.2 PCT.

The application is therefore considered to contain the following separate groups of invention:

- (1) LCM followed by analysis of the total protein content (claims 1, 2, 15, 16, 25, 26)
- (2) LCM followed by immunological analysis of selected protein components (claims 4 - 8, 14, 18, 19; claims 34 to 40 in part),

(3) LCM combined with methods of sequence analysis of one or more proteins (claims 9 - 11, 20, 21, 26 - 28)

(4) LCM and analysis of cellular components other than proteins (claims 34 - 40, in part)

SECTION V:

- 3.1 D1 discloses LCM and in particular discloses its advantages over other methods of preparation of purified cell samples (D1, abstract). According to fig. 3, cell samples obtained by LCM can be subjected to molecular analyses at the nucleic acid level, such as DNA or RNA analyses by means of oligonucleotide/cDNA arrays.

Thus, D1 anticipates the methods as defined in claims of claims 34, 35, 37, 39 and 40 (Art. 33(2) PCT) and renders obvious the additional features given in claims 36 and 38 (Art. 33(3) PCT).

- 3.2. D2 concerns genetic analysis of LCM purified cellular samples, by means of PCR (Examples 2 - 5). In view of the feasibility of PCR analysis as shown in D2, a skilled person would consider the combination of this technology with hybridization of solid phase bound probes, e.g. oligonucleotide arrays as disclosed in D1 as obvious.

Thus, the subject-matter of claims 34 - 40 lacks an inventive step in view of D2 when read in conjunction with D1, contrary to Art. 33(3) PCT.

4. Having regard to p. 275, col. 1, lines 20 - 29, analyses of the protein content have been made. These tests revealed a linearity of the amount of protein per cell, or per spot captured. In addition, immunohistochemical staining and "soluble" immunoassays for single proteins have been performed (p. 275, col. 2, lines 1 - 4).

These assays essentially involve the steps as broadly outlined in claim 1.

Consequently, D1 is detrimental to the novelty of claim 1 (Art. 33(2) PCT).

**INTERNATIONAL PRELIMINARY
EXAMINATION REPORT - SEPARATE SHEET**

International application No. PCT/US00/04023

5. D1 explicitly suggests the application of this techniques in comparative testing (p. 276, col. 1, lines 20 - 29). It therefore renders obvious the subject-matter of claim 15, contrary to Art. 33(3) PCT.
6. Preliminary immunoassays mentioned in D1 ("immunohistochemical staining and soluble immunoassays") proved that the cellular proteins are immunologically preserved (fig. 3, and p. 275, col. 2, lines 1 - 4).

This teaching motivates a skilled person to analogously apply known immunocytochemical analyses to LCM purified samples. Thereby one would arrive at the method as defined in claims 4, 5, 8, 12, 13, 22 - 24 (Art. 33(3) PCT).

7. Claims 2, 3, 6 (step b), 7, 14, 16 - 19, 25 (step b), relate to (i) features that are commonly applied in immunocytochemical analyses, to (ii) the analysis of conventional tumour markers or (iii) to procedural modifications at which one arrives in the course of commonly applied laboratory routine procedures for optimization of analytical methods.

These features are therefore not considered to impart an inventive activity, contrary to Art. 33(3) PCT.

8. The relevant prior art does not disclose or suggest the combination of LCM purification with a sequence analysis of proteins or with protein fingerprinting.

Thus, the subject-matter of claims 9 - 11, 20, 21, 26 - 28, appears to meet the requirements of Art. 33(2) and (3) PCT.

SECTION VII:

9. Contrary to the requirements of Rule 5.1(a)(ii) PCT, the relevant background art disclosed in the document D1 is not mentioned in the description, nor is this document identified therein.

SECTION VIII:

**INTERNATIONAL PRELIMINARY
EXAMINATION REPORT - SEPARATE SHEET**

International application No. PCT/US00/04023

10. The vague and imprecise statement in the description on page 42, lines 18 - 20 implies that the subject-matter for which protection is sought may be different to that defined by the claims, thereby resulting in lack of clarity (Article 6 PCT) when used to interpret them (see also the PCT Guidelines, III-4.3a).



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁷ : G01N 33/53	A2	(11) International Publication Number: WO 00/49410 (43) International Publication Date: 24 August 2000 (24.08.00)
(21) International Application Number: PCT/US00/04023 (22) International Filing Date: 16 February 2000 (16.02.00) (30) Priority Data: 60/120,288 16 February 1999 (16.02.99) US (71) Applicant (for all designated States except US): THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY DEPARTMENT OF HEALTH & HUMAN SERVICES, THE NATIONAL INSTITUTES OF HEALTH [US/US]; Office of Technology Transfer, 6011 Executive Boulevard, Suite #325, Rockville, MD 20852 (US). (72) Inventors; and (75) Inventors/Applicants (for US only): LIOTTA, Lance, A. [US/US]; 8601 Bradley Boulevard, Bethesda, MD 20817 (US). SIMONE, Nicole [US/US]; 16 Balsam Court, Lawrenceville, NJ 08648 (US). EMMERT-BUCK, Michael [US/US]; 13620 Cedar Creek Lane, Silver Spring, MD 20904 (US). PETRICOIN, Emmanuel, F., III [US/US]; 2805 Feather Ridge Court, Dunkirk, MD 20754 (US).		(74) Agent: NOONAN, William, D.; Klarquist, Sparkman, Campbell, Leigh & Whinston, Leigh, Suite 1600 - One World Trade Center, 121 SW Salmon Street, Portland, OR 97204 (US). (81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published <i>Without international search report and to be republished upon receipt of that report.</i>
(54) Title: METHODS AND DEVICES FOR THE ISOLATION AND ANALYSIS OF CELLULAR PROTEIN CONTENT (57) Abstract <p>The present invention describes devices and methods for performing protein analysis on laser capture microdissected cells, which permits proteomic analysis on cells of different populations. Particular disclosed examples are analysis of normal versus malignant cells, or a comparison of differential protein expression in cells that are progressing from normal to malignant. The protein content of the microdissected cells may be analyzed using techniques such as immunoassays, 1D and 2D gel electrophoresis characterization, Western blotting, liquid chromatography quadrupole ion trap electrospray (LCQ-MS), Matrix Assisted Laser Desorption Ionization/Time of Flight (MALDI/TOF), and Surface Enhanced Laser Desorption Ionization Spectroscopy (SELDI). In addition to permitting direct comparison of qualitative and quantitative protein content of tumor cells and normal cells from the same tissue sample, the methods also allow for investigation of protein characteristics of tumor cells, such as binding ability and amino acid sequence, and differential expression of proteins in particular cell populations in response to drug treatment. The present methods also provide, through the use of protein fingerprinting, a rapid and reliable way to identify the source tissue of a tumor metastasis.</p>		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

- 2 -

Because of these limitations, a number of direct comparisons between tumor cells and normal cells have not been achievable. There has been no way to directly compare, without the danger of cross-contamination, the spectrum of proteins contained in normal cells with the proteins in tumor cells in a single tissue. Many hypotheses about altered protein levels in tumor cells have been based on work on cells lines, and the ability for continued growth in culture by the cell line injects yet another variable into the results. There has also been no way to directly quantify differences in protein amount between tumor and normal tissue. Much of the work in this area has been done using immunohistochemistry, imparting the limitations as to quantification and specificity discussed above. Moreover, there has been no way to compare the protein content of various stages of tumor development, or to compare the characteristics of proteins found in tumor cells to those in normal cells. Nor could a protein's amino acid sequence or binding characteristics be performed. And, because such comparative protein studies could not be done, it was difficult to reliably determine the source of a tumor metastasis, unless the probable tumor source was already known.

SUMMARY OF THE DISCLOSURE

Proteomic research has been complicated by the fact that cells undergoing the progression to a diseased state may constitute less than 5% of the volume of a tissue biopsy sample. In a mixture of diseased and normal cells, differential protein expression in the diseased cells may be masked by the "background" of proteins expressed in normal cells. Immunohistochemistry cannot provide a solution to this problem, because it can provide only the location of the targeted antigen. This technique is ineffective at providing quantitative data because it is not possible to calibrate the intensity of immunohistochemical staining with the actual number of antigen molecules in the stained tissue cells. Additionally, many antibodies cannot differentiate between pro-enzyme and active enzyme species. Immunologically based studies cannot easily provide a complete picture of a cell's protein contents.

The present invention describes devices and methods for extracting proteins from samples of microdissected cells, and applying various analytic processes to the extracted proteins, such as

immunoassays, 1D and 2D gel electrophoresis characterization, Western blotting, Matrix Assisted Laser Desorption Ionization/Time of Flight (MALDI/TOF), liquid chromatography quadrupole ion trap electrospray (LCQ-MS), and Surface Enhanced Laser Desorption Ionization Spectroscopy (SELDI). These methods allow for direct comparison of qualitative and quantitative protein content of tumor cells and normal cells from the same tissue sample. The methods also allow for investigation of protein characteristics of tumor cells, such as binding ability and amino acid sequence. The present methods also provide, through the use of protein fingerprinting, a rapid and reliable way to identify the source tissue of a tumor metastasis.

In this method, the protein content of a selected population of cells from a tissue sample is analyzed, by extracting the population of cells from the tissue sample using laser capture microdissection (LCM). The population of cells that is extracted can be, for example, cells of a particular cellular substructure (such as cells from epithelium on the lumen of an organ, or pockets of cells that have undergone malignant transformation against a background of a larger population of more normal cells). Proteins are isolated from the isolated population of cells, and characteristics of the proteins may be analyzed to provide information about the protein characteristics of the selected isolated population of cells.

In particularly disclosed examples, differential expression of proteins in isolated malignant cells can be used to study changing patterns of protein expression during malignant transformation. In other examples, cells at different stages of biological transformation (such as neoplastic progression from normal cells to metaplastic cells to invasive carcinoma) can be studied to analyze differential protein expression at different stages of neoplastic progression. Similar methods can be used to analyze cells for therapeutic purposes (such as selecting drugs targeted against expression of particular proteins), or in drug response assays (to assess changes in protein expression as an indication of drug response).

BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 is a relative size comparison of the laser beam diameter and the epithelial tissue sample being microdissected. Laser Capture Microdissection (LCM) was performed to selectively

transfer only the epithelial lining of the prostate gland to the polymer film. The 30 micron laser beam spot size is shown in relation to the thickness of the gland. EP: epithelial, LU: lumen, stroma are as marked.

Figure 2 shows how cells of interest are selected using LCM and transferred onto a cap, where the proteins are solubilized directly into a tube.

Figures 3A and B are graphic representations of the number of molecules of PSA as compared to the number of laser shots used to harvest the cells. Figure 3A shows the results of a 500 shot sample of tumor cells serially diluted to verify sensitivity. RLU values were converted to PSA molecule numbers. Linear regression indicated an r value of 0.998. Figure 3B reports the results of a linearity analysis conducted on six different tissue sections from the same patients. The number of laser shots are indicated, $r = 0.95$.

Figure 4 is a table showing the number of PSA molecules, the coefficient of variation of the process, and the mean number of cells used in the immunoassays. These sensitivity and precision analyses were done on 10 separated microdissection replicates. The mean readout in RLUs is reported as well as the corresponding number of PSA molecules. The sensitivity, defined as two standard deviations above background, was one laser shot. Imprecision (%CV) was inversely correlated with number of shots per specimen.

Figure 5 is a table comparing the number of PSA molecules with the immunohistochemistry score. Independent immunohistochemistry scoring of coded specimens was done by a pathologist and scored as high (+++), medium (++), and low (+). PIN: prostate intraepithelial neoplasia, Tumor: invasive carcinoma, Normal: histologically normal prostate glands. The relative concentrations of PSA per cell among different progression stages varies greatly and this corresponds directly to the semiquantitative immunohistochemistry scoring.

Figures 6A, B, and C are 2-D or 1-D gel comparisons of the proteins in microdissected normal and tumor epithelium. Fifty thousand cells were procured by LCM, directly lysed in IEF buffer and run on a 3-10 NL Pharmacia IPG IEF strip for 100kVhr. The second dimension runs were performed on 8-18% linear gradient SDS-PAGE gels and the gels were stained with silver. Figures 6A and 6B show match tumor and normal fingerprints for each patient. A representative pI

and molecular weight ruler for direct comparison and alignment is shown in panel A. Figure 6C shows the alpha-tubulin immunoblot that was used to normalize for relative protein load.

Figure 7 is a 2-D gel comparison of microdissected normal and tumor epithelium compared to a Western blot using an anti-pan-cytokeratin type II antibody. The gels were run as described for Figure 6. The completed gel was transferred to PVDF membrane and western blotted with a 1:1000 dilution of anti-pan type II cytokeratin.

Figure 8 is a 2-D gel comparison of microdissected normal, tumor epithelium, and stroma tissue indicating the differences by circling the altered proteins. The gels were prepared and run as described in connection with

Figure 6.

Figure 9 is a 2-D gel comparison of microdissected normal and tumor epithelium as compared to whole tissue cryostat where circles indicate the locations of the "altered" proteins. The gels were prepared and run as described in Figure 6.

Figure 10 is a 1D-gel anti-PSA Western blot of cell lysates from microdissected normal and tumor prostatectomy specimens. Lanes 1 & 3 are benign epithelium and lanes 2 & 4 are from malignant epithelium.

Figures 11A and B are anti-PSA Western blots, where lanes 1-4 are benign epithelium and lanes 5-8 are malignant. Lanes 1 & 5 are untreated, lanes 2 & 6 are with ACT added, and lanes 3 & 7 are incubation controls, while lanes 4 & 8 are ACT added with 120 minutes of incubation at 37° C.

Figures 12A and B are anti-PSA Western blots showing complexed and non-complexed species.

Figures 13A, B, and C show data which indicates SELDI protein profiles of LCM-derived cellular lysates are reproducible and sensitive. Figure 13A shows two separate microdissections of prostate tumor epithelium from the same tissue section from the same patient (1200) cells each) which were analyzed by SELDI protein fingerprinting. The raw mass spectroscopic mass map is shown for each microdissection along with the Gel-View® display from the same data set. Figure 13B shows two separate microdissections of prostate tumor epithelium from a tissue section from

two different patients (1200 cells each) which were analyzed by SELDI protein fingerprinting. The raw mass spectroscopic mass map is shown for each microdissection along with the Gel-View[®] display from the same data set. Figure 13C shows four separate microdissections of decreasing number of cells that were analyzed by SELDI protein fingerprinting. The Gel-View[®] display is shown as a representation of the direct alignment of each of these four mass spectra to each other.

Figures 14A, B, and C show that SELDI protein profiles of LCM-derived cellular lysates are discriminatory between different tumor epithelial cell types from different patients and between tumor and normal epithelial cells from the same patient. In Figures 14A and 14B LCM derived tumor epithelial cells (1200 cells) from prostate, breast, and colon frozen tissue sections were separately acquired and analyzed via SELDI. The Gel-View[®] representation is shown in Figure 14A and the spectrographic mass profile is shown in panel B. Figure 14C shows the SELDI analysis of four separate patient-matched microdissections of 1200 cells of colon normal epithelium, colon tumor epithelium, colon tumor epithelium from the colon tumor that has metastasized to the liver, and normal liver cells next to the metastasis. The Gel-View[®] display is shown as a representation of the direct alignment of each of these four mass spectra to each other.

Figure 15 is a SELDI fingerprint comparison between a variety of tumor types.

Figure 16 shows a device developed for solubilizing proteins in cells taken from a biological specimen by LCM.

Figures 17A and 17B are SELDI analyses of microdissected esophageal epithelium showing proteins dysregulated in a disease-specific manner. Figures 18A and 18B are SELDI analyses of 8 different esophageal cancer cases, where three separate microdissections of eight different patients' matched tumor and normal cells were subjected to SELDI analysis via the use of a hydrophobic interaction C18 binding surface. Each replicate was run in triplicate, giving a total of 72 data points for each protein peak analyzed. The analysis of the protein fingerprint in the low mass region is shown in Figure 17A, the higher mass region in Figure 17B. A representative mass map from one case (case #1) is shown on the left side of each panel with the normal and tumor fingerprint shown (top and bottom, respectively) for each mass region. A gel-like representation is displayed for that particular case as well as the fingerprint for two other cases. Proteins 1, 2, 6,

and 7 are labeled for orientation. All cases analyzed in the study set were then subjected to analysis as a ratio of relative intensity of the selected proteins to one another and the statistical results shown on the right side of each figure. Figure 17A: average C.V. = 12.7%, 29.4% for the normal and tumor microdissections respectively. Figure 17B: average C.V. = 10.5% and 18.9% for the normal and tumor microdissections, respectively.

Figure 18 shows the SELDI analysis of prostate carcinogenesis. Figure 18A shows a mass map that represents the profile from 1500 normal, pre-invasive neoplasia (PIN) and invasive carcinoma cells acquired by LCM from one case (case #2). Additionally, the corresponding patient-matched stromal cells (1500 cells) were also microdissected for analysis. Figure 18B shows a gel-like image of the raw mass data shown in Panel A. All samples from this patient were run in triplicate, with the representation of one experiment shown. Two proteins, A and B, having molecular weights of 28,000 and 32,000 respectively, were found to be reproducibly differentially expressed in this patient and are indicated in both Figures 18A and 18B. Figure 18C shows the ratio analysis of A vs. B from an additional study set of two other (cases #1 and #3) patient matched tumor and normal prostatic epithelium (average C.V. = 17.2 % and 10.1% for the tumor and normal microdissections, respectively).

Figure 19 is a diagram of the multiplexed tissue array method for a high throughput target validation and drug tissue interaction assay, using microdissected human breast cells in various stages of malignancy as an example biological sample.

Figures 20A, 20B and 20C are representative results using colorimetric and chemiluminescent detection methods for prostate soluble antigen (PSA). The rows of the upper arrays are in all three cases (1) a protein standard, (2) prostate stroma, and (3) normal prostate tissue, while the lower arrays include (4) prostate intraepithelial neoplasia (PIN), (5) tumor tissue, and (6) invasive tumor tissue. The amount of total protein loaded on the gel is reduced across the rows. Figure 20A shows the colorimetric results, Figure 20B is the positive and Figure 20C is the negative image of the fluorescence results.

Figures 21A, 21B, and 21C diagram the reproducibility of protein analysis for samples microdissected from a mixed sample of epithelial cells of the esophagus. All the following data

091367-0422

INS
A²

was obtained from normal cells present in the sample. Figure 21A shows the reproducibility of the annexin I protein data in normal cells over a variation of "shot" size within one slide and between multiple slide sets. Figure 21B shows a histogram of the coefficient of variance for these data sets. Figure 21C graphically shows reproducibility of the total protein obtained from the cells as shown by fluorescence detection.

Figure 22 shows the results of interaction between immobilized binding agents and biotin-labeled lysates from microdissected normal and tumor cells.

DETAILED DESCRIPTION OF THE INVENTION

Laser Capture Microdissection (LCM) is a recently developed technology that enables the user to obtain pure cell populations from stained heterogeneous tissue under direct, high power microscopic visualization. See Emmert-Buck et al., Laser Capture Microdissection, 274 Science 998 (1996); Bonner et al., Laser Capture Microdissection: Molecular Analysis of Tissue, 278 Science 1481 (1997). A laser beam focally activates a special transfer film that specifically bonds to cells identified and targeted by microscopy within the tissue section. The transfer film with the bonded cells is then lifted off the thin tissue section, leaving all unwanted cells behind. This process allows the sample to include only cells exhibiting the desired morphology for study. This application of LCM to the analysis of the DNA of isolated cells is described in U.S. Patent No. 5,843,657, issued to Liotta et al., which is incorporated by reference.

Briefly, the LCM process works as follows. First, the transparent transfer film is applied to the surface of the tissue section. Under the microscope, the operator views the thin tissue section through the glass slide on which it is mounted and chooses microscopic clusters of cells to study. When the cells of choice are in the center of the field of view, the operator pushes a button that activates a near IR laser diode integrated with the microscope optics. The pulsed laser beam activates a precise spot on the transfer film immediately above the cells of interest. At this precise location the film melts and fuses with the underlying cells of choice. When the film is removed, the chosen cell(s) are tightly held within the focally expanded polymer, while the rest of the tissue is left behind. The exact morphology of the procured cells is retained and held on the transfer film,

ensuring preservation of the cells' intracellular components such as DNA, RNA, and proteins for future analysis. The removed transfer film and cells are transferred onto a plastic cap (referred to as the LCM cap) for subsequent analysis.

Isolation of these preserved intracellular components from the cells on the LCM cap has necessitated the development of new procedures, buffers, and devices. In particular, the present methods utilize a new procedure for extracting proteins from very small sample sizes, on the order of about 1500 to about 5 cells, the number obtained in a typical LCM laser shot. This procedure generally involves the extraction of proteins in one solubilizing step, using a very small volume of a unique buffer. To facilitate the handling of such small volumes and small sample sizes, a device in which the solubilization step can be conveniently performed was developed. The results of this new procedure are intact proteins, substantially free of cross-contamination from other nontumor or normal cell types. The isolated proteins maintain activity, allowing analysis through any number of immunological and biochemical assays.

The buffers for the protein isolation step can include one or more of buffer components, salt, detergents, protease inhibitors, and phosphatase inhibitors. In particular, one effective buffer for extracting proteins to be analyzed by immunohistochemistry includes the buffer Tris-HCl, NaCl, the detergents Nonidet® P-40, EDTA, and sodium pyrophosphate, the protease inhibitors aprotinin and leupeptin, and the phosphatase inhibitors sodium deoxycholate, sodium orthovanadate, and 4-2-aminoethyl benzenesulfonylfluoride (AEBSF). Another salt which could be used is LiCl, while glycerol is a suitable emulsifying agent that can be added to the fraction buffer. Additional protease inhibitors include soybean trypsin inhibitor and pepstatin. Other suitable phosphatase inhibitors include phenylmethylsulfonyl fluoride, sodium molybdate, sodium fluoride, and beta-glycerol phosphate. For 2-D gel analysis, simple lysis with a 1% SDS solution was effective, while ultimate analysis using the SELDI process required Triton-X-100, a detergent (Sigma, St. Louis, MO), MEGA 10® (ICN, Aurora, OH), and octyl B-glucopyranoside (ESA, Chelmsford, MA) in a standard PBS base. Another buffer which was used prior to 2-D gel analysis was 7M urea, 2M thiourea, CHAPS, MEGA 10, octyl B-glucopyranoside, Tris, DTT, tributyl phosphine, and Pharmalytes. A preferred 1:100 concentration buffer is as follows:

Material	Concentration of Stock Solution	Amount
50 mM Tris-HCL	1 M	1.25 ml
1% NP-40	10%	2.5 ml
.1% Na Deoxycholate	10%	250 μ l
150 mM NaCl	3 M	1.25 ml
4 mM EDTA	.25 M	400 μ l
Aprotinin	10 mg/ml	25 μ l
Leupeptin	10 mg/ml	25 μ l
10 mM Na Pyrophosphate		.115 g
2 mM Na Orthovanadate		.004g
AEBSF	100 mM	250 μ l

The buffer is made and diluted 1:100 in distilled water for use. The buffer must be kept frozen at -20°C . It can only be used unfrozen for a few hours. In all cases, the buffer is used in very low volumes, from about 1 μ l to about 15 μ l, and is applied directly to the laser capture dissected cells while still on the LCM cap.

To simplify the process of solubilizing the proteins directly on the LCM cap, a device was developed to handle the small volumes. This device (shown in Fig. 16) includes a small chamber 1 where the solubilization process can occur. The chamber has an upper opening 2 structured such that it can directly accept the LCM cap with its adhered cells. The LCM cap is placed in the chamber 1 with the surface having cells upon it facing the interior of the chamber. Once the LCM cap is attached to the device, the cells are therefore strategically positioned within the chamber and solubilization of the proteins will occur upon introduction of the solubilization buffer. The chamber is supplied with at least one inlet port 3, which can be equipped with a syringe 4 as a means of introducing the small volume of the solubilizing buffer into the chamber 1. The inlet port 3 is connected to the chamber by a narrow inlet canal 5, where liquids placed into the canal will move toward the solubilization chamber by capillary action. The device can include more than one inlet chamber, if desired, each equipped with a means of introducing liquid, such as a syringe. The device also includes an outlet port 6, connected to the chamber 1 with a narrow outlet canal 7, which can be supplied with a means of collecting and removing the solubilized proteins. One

embodiment of this device has the chamber 1, the inlet ports 3, inlet canals 5, outlet port 6, and outlet canal 7, all machined in a hard plastic block, such as lucite.

Once the proteins have been solubilized, a number of different immunological or biochemical analyses can be used to characterize the isolated proteins. Because the cells are usually initially identified for LCM capture based on particular morphological characteristics, the results of these assays are assured to be representative of the cell type collected.

1 WS
A3
1 One type of assay that can be performed is a soluble immunoassay, where an antibody specific for a protein of interest is used. The antibody can be labeled with a variety of markers, such as chemiluminescence, fluorescence and radioactive markers. For best results, the assay used should be of high sensitivity, such as a microparticle enzyme immunoassay (MEIA). By applying a calibration curve used to estimate immunodetected molecules in serum, the number of molecules per cell can be estimated. Thus, the presently described methods provide a quantitative immunoassay, which can measure the actual number of the protein molecules of interest *in vivo*.

2 A second type of assay that can be used to analyze the extracted proteins is two-dimensional polyacrylamide gel electrophoresis (2D PAGE). By running both proteins extracted from normal cells of the sample and proteins extracted from tumor cells of a sample, and comparing the blots, differential protein expression can be seen. In particular, by scanning the stained gels into a computer, and using image comparison software, the location of proteins that are present in one cell type and absent in the other can be determined. Furthermore, these altered proteins can be isolated from the gel where they are present, and mass spectroscopy MS-MS sequencing can be used to identify the protein, if the sequence exists in a database. In this way, the protein differences between normal and tumor cells can be more fully understood. Additionally, proteins of interest isolated from a 2-D gel may be used in binding studies, where the protein is functionally tested for an alteration in the ability to bind with a putative or known ligand. Finally, this comparative analysis need not be between normal and tumor cells, but can be between isolated stages of a tumor, where the different stages exhibit sufficient morphological differences to allow separate isolation of populations using the LCM technique.

A further analysis that may be performed involves the use of the surface enhanced laser desorption ionization spectroscopy technique, or SELDI (Ciphergen Biosystems Inc., Palo Alto, CA). This process can separate proteins which would not be separately focused by 2-D gel analysis, in particular those proteins which are very basic, very small (< 7000 daltons) or are expressed at low or moderate levels in the cells. The lower level of expression becomes critical in these experiments because of the extremely small sample size of cells used. SELDI also separates proteins more rapidly than gel analysis. SELDI utilizes a "protein chip" that allows for desorption and detection of intact proteins at the femtomole levels from crude samples. Proteins of interest are directly applied to a defined small surface area of the protein chip formatted in 8 to 24 predetermined regions on an aluminum support. These surfaces are coated with defined chemical "bait" matrices comprised of standard chromatographic supports, such as hydrophobic, cationic, or anionic or biochemical bait molecules such as purified protein ligands, receptors, antibodies, or DNA oligonucleotides. See Strauss, New ways to probe the molecules of life, 282 Science 1406 (1998). In the case of LCM collected samples, the solubilized proteins are applied to the surface of the SELDI chip. Binding of the proteins to the surface is dependent on the nature of the bait surface and the wash conditions employed. The mixture of bound proteins is then characterized by laser desorption and ionization and subsequent time of flight mass analysis generated from a sensitive molecular weight detector. This data produces a protein fingerprint for the sample, with SELDI having a practical resolution and detection working range of 1000 to 300,000 daltons, depending on the energy absorbing molecule utilized and the bait surface/wash conditions employed.

The produced protein fingerprints have proven to be both disease-specific and organ-specific. That is to say, the protein fingerprint of a tumor from a particular tissue type remains characteristic of that tissue type, whether it is normal, tumor, or a metastasis. This allows a determination of the origin of an unknown metastasis to be made, through comparison to protein fingerprints of normal or tumor tissue of likely organ sources.

The principles of the invention are further illustrated by the following Examples.

The thawed sample was held at 4°C for no longer than 2.5 hours prior to introduction into the immunoassay module.

Figure 1 compares the size of a 30 μ m laser shot with the size of an example prostate gland that was microdissected by movement of the joystick. The yield of procured pure epithelial or carcinoma cells, and the precision of cellular procurement, were tested by visually counting the number of cells removed from the tissue and transferred to the film. Table 1 compares the number of laser shots with the average total number of microdissected cells.

Table 1

	1 shot case C	15 shots case C	100 shots case B
Mean Cells	6.78	102	506.2
Standard Deviation	3.73	3.39	11.98
Coefficient of Variation	55.1%	3.33%	2.37%

- 10 A standard laser spot diameter of 30 μ m encompasses 5-7 cells. Individual tissue cells can vary in their packing density, their shape and their volume. Consequently, the imprecision of the cell yield is greater with fewer laser shots.

Solubilization of proteins from LCM procured cells

- 15 Extraction of the proteins from the exposed transferred cells was done by pipetting a small volume of buffer directly on the inverted capture surface of the polymer film (Figure 2). Following placement of 5 μ l of extraction buffer onto the transfer surface containing the tissue cells, visual confirmation was obtained establishing the complete solubilization of the stained cells. The transfer cap with the extracted cellular protein was inserted into the mouth of a vial containing the immunoassay buffer. After analysis, the transfer caps were counterstained to ensure complete solubilization of the cells. The diluted extraction buffer did not interfere with the immunoassay background level or linear calibration.
- 20

Extraction Buffer

The final buffer composition was a 1/1000 dilution of the following stock: 50mM Tris HCl, 1% NP-40, 0.1% Na Deoxycholate, 150mM NaCl, 4mM EDTA, Aprotinin (10mg/ml), Leupeptin (10mg/ml), Na Pyrophosphate (10mM) Na orthovanate (2mM), and AEBSF (100mM).

5 Assay Principle

The Immulite Third Generation PSA assay (Diagnostic Products Corp., Los Angeles, CA) was adapted to measure PSA solubilized from tissue cells procured by LCM. Photon production is measured by a luminometer (output: relative light units (RLUs)). Negative tissues or zero controls produced a value of 80140,000 RLUs, compared to PSA positive samples that ranged from 600,000 to 10,000,000 RLUs.

PSA immunoassay: Microparticle Enzyme Immunoassay (MEIA)

PSA was measured by an automated two site chemiluminescent assay, using the ultrasensitive PSA reagent kit on the Immulite immunoassay analyzer (Diagnostic Products Corp., Los Angeles, CA). RLUs reflect the photons detected by the photomultiplier tube, which is proportional to the concentration of PSA. The sensitivity of the assay is .004 ng/mL of PSA, or approximately 4×10^6 molecules of PSA per assay.

Immunohistochemistry

Immunohistochemistry staining for PSA was conducted as follows. The frozen sections were desiccated and then fixed in acetone. Following a wash with 3% goat serum, primary antibody incubation was 1 hour at room temperature. The secondary antibody was labeled by Avidin/Biotin and the substrate system was Peroxidase/DAB. The secondary reaction was performed essentially as suggested by the commercial product insert.

Calibration Curve

The calibration curve used for measurement of PSA in serum according to the Immulite package insert was applied to the measurement of cellular tissue proteins procured by LCM. The calibration curve designed for serum was reproduced with the LCM extracted cellular proteins in the buffer solution. Serum or buffer samples with a known concentration of PSA were mixed with equal volumes of 100 laser shots of PSA negative tissue cells. There was approximately 100%

recovery in all cases, with no detectable elevation of the zero dose or diminution of the signal. The number of laser shots of actual tissue cells was compared to the calculated number of PSA molecules for individual patient cases as shown in Figure 3. Linear regression analysis yielded an r value of greater than 0.95 over a dynamic range of 0.004 ng/mL to 1 ng/mL.

5 **Sensitivity**

INS
A5
1
The detection limit of the assay for microdissected cellular proteins was 0.004 ng/ml PSA as defined as the concentration two standard deviations above the signal response of a sample free of PSA or a PSA negative tissue. The sensitivity achieved with this criteria was one 30 μ m laser shot (5-7 cells).

10 **Imprecision**

The imprecision of cell capture for 100 shots is 3.3% C.V. compared to a C.V. of 15.8% for the PSA measured in the proteins extracted from 15 laser shots. In keeping with the assumed biologic heterogeneity, one laser shot exhibits a PSA measurement C.V. of 60.2%, even though the mean magnitude of the signal (804,416 RLU) is substantially greater than the mean value for combined 100 shots of background tissue (132,759) (Figure 4). Thus, capturing 15 (analytical sensitivity threshold) to 100 laser shots of a tissue sample (this takes less than five minutes) provides an acceptable level of imprecision for a routine assay.

Correlation with Tissue Immunohistochemistry

Analysis using LCM coupled with PSA immunoassays for PSA was conducted on prostate tissue sections that contained normal epithelium, carcinoma, and prostate intraepithelial neoplasia (PIN). Based on the imprecision analysis described above, the number of laser shots was 100. For each specimen studied, a standard curve was prepared for a series of different numbers of laser shots to verify that conclusions based on 100 shots remained in the linear portion of the curve (Fig 3B). Immunohistochemistry for Prostate Specific Antigen was conducted on adjacent sections.

25 The PSA immunoreactivity of cellular populations identical to those sampled by LCM on matched coded sections was scored independently and ranked on a scale of zero to five plus (Figure 5). The average number of molecules per cell ranged from 10^4 to 10^6 . The immunohistochemistry scoring values paralleled the quantitation and mirrored the heterogeneity in PSA production by normal and

neoplastic cell populations. For example, in case C the normal epithelium contained 6.3×10^6 molecules and scored three plus by immunohistochemistry. In contrast, the PIN cells contained 3.7×10^5 molecules and scored two plus, and the tumor cells contained 1.99×10^4 , and stained one plus.

5 Application of this new technology, as reported in Figure 5, provides quantitative confirmation of the heterogeneity in PSA expression that was previously detected only by qualitative staining. The average numbers of PSA molecules harvested per cell ranged over several logs. An immunohistochemical staining difference could be discriminated only if there was greater than a ten-fold difference in PSA molecule number per cell.

The present technology provides one of the first direct estimates of the actual number of protein molecules per tissue cell *in vivo* for a single specific known protein of moderate to low abundance. The number of total PSA molecules in normal prostate epithelium ranged from 10^4 to 10^6 . PSA is an important serum analyte used to clinically monitor prostate cancer, but it is not a specific marker of prostate cancer. Previous investigators have reported great heterogeneity in the intensity of PSA immunohistochemical staining among various neoplastic and non-neoplastic populations in the prostate. Populations of microdissected cells of a pure histologic class would be expected to contain some level of heterogeneity in PSA expression among the population members, as presently seen.

20 **EXAMPLE 2**
Comparative Protein Analysis of Normal and Cancerous Esophageal Epithelium
Patients and Tissue Samples

The two specimens studied were from patients who presented to the Shanxi cancer Hospital in Taiyuan, Shanxi Province, People's Republic of China and diagnosed with esophageal cancer. Both patients were considered candidates for curative surgical resection. Both cases were stage two squamous cell carcinomas of the esophagus.

Microdissection

Frozen section slides were prepared from each case and microdissected by LCM (Pixcell 100, Arcturus Engineering, Mountain View, CA) by selectively aiming for and capturing normal

epithelium or tumor cells. LCM was performed as previously described except AEBSF (Boehringer Mannheim) was added to the staining baths at a final concentration of 2 mM to inhibit proteases. In each case 50,000 cells were procured. Based on careful review of the histologic sections each microdissection is estimated to contain >98% of desired cells (normal versus tumor).

5 Sample Preparation

One hundred microliters of IEF lysing solution containing 7M Urea, 2M Thiourea, 4% CHAPS, 1% MEGA-10, 1% Octyl- β -Glucopyranoside, 40 mM Tris, 50 mM DTT, and 2 mM tri-butyl phosphine (TBP) and 0.5% (v/v) Pharmalytes was applied directly to the microdissected cells adhered on the LCM cap, placed into an eppendorf tube and vortexed vigorously for one minute until all cells were completely lysed. The IEF lysing solution was then re-applied to another cap containing cells from the same microdissected material and the procedure repeated until each 100 μ l contained lysate from 50,000 cells (approximately 7000 LCM transfer pulses).

2D PAGE and Image Analysis

First-dimension isoelectric focusing was carried out on a Pharmacia Immobiline IPG Dry-strip system essentially as described by the manufacturer. Pre-cast immobilized pH gradient strips (18 cm, 3-10 non-linear) were employed for the first dimensional separation for a total focusing time of 120kVh. The strips were re-equilibrated with a solution containing SDS and Tris pH 6.9, reduced with TBP (2 mM), alkylated with iodoacetamide (2.5% w/v), and directly applied to a 8-18% linear gradient SDS-PAGE gel for electrophoresis overnight at 40 volts constant voltage. The gels were stained with silver and direct scanning and image analysis was performed using an Umax scanner with Adobe Photoshop software and a Tektronix IISDX photographic-quality printer. Scanned images were analyzed and compared using the MELANIE II software package (BioRad). Comparison of protein fingerprints were performed using images representing protein spots readily apparent by direct visualization. Only spots that were present/completely absent between normal-tumor cells were defined as altered. Each experiment was performed in duplicate and produced similar results (data not shown). Normalization of sample load was by anti- α -tubulin immunoblot analysis prior to the first-dimension run. Scoring of the blots included comparison of multiple exposure times.

Analysis of alpha - tubulin

Ten μ l of the IEF lysate was diluted 1:1 in 2X SDS sample buffer, boiled for 5 minutes, and applied to a 4-20% NOVEX Tris-glycine SDS gel and electrophoresed for 1 hour.

Immunoblotting was performed for 1.5 hour using a BIO-RAD Semi-dry blotting apparatus with
5 Immobilon PVDF membrane as the capture surface. Blots were blocked with 1X TBS containing 1% ovalbumin and incubated with a monoclonal anti-alpha tubulin antibody for 3 hours. Anti-alpha tubulin antibodies were purchased from SIGMA and used at final dilution of 1:1000. Blots were washed with 1X TBS 3 times for 5 minutes and secondary antibody was added. HRP-coupled rabbit anti-mouse secondary antibodies were purchased from SIGMA and used at a final dilution of
10 1:10,000. Blots were washed and ECL substrate (Amersham) was added for chemiluminescent detection via autoradiography on Kodak Bio-Max film.

Mass Spectrometry

A separate 2D PAGE gel was run with microdissected tumor from case #1 except the gel was stained and analyzed with zinc-imidazole. Two proteins which were aberrantly regulated in
15 both tumors were chosen for mass spectrometry MS-MS sequencing. The acrylamide plug was taken from the gel and washed once with HPLC-grade water for 5 minutes, and subjected to in gel tryptic digestion as previously described .

In-gel proteolytic digestion

INS
AS
20 Gel pieces were excised and washed by end-over-end mixing in 12 ml 30% methanol for 30 minutes (room temperature), washed twice for 30 minutes with 150 μ l of 1:1 acetonitrile/100 mM ammonium bicarbonate pH 8. Each spot was sliced into fourths and rehydrated 10 μ l of 100 mM ammonium bicarbonate pH 8 containing trypsin (2 pmol/ μ l) (Promega modified trypsin). Additional 10 μ l of digestion buffer without trypsin was then added. After incubation at 37°C for 20 hours, the condensate was collected by spinning the tubes briefly and excess liquid was removed
25 into a new tube. Peptides remaining in the gel matrix were extracted twice with 150 μ l 60% aqueous acetonitrile, 0. 1% TFA at 30°C for 30 min. The extracted volume were reduced to about 5 μ l using an Eppendorf speed-vac concentrator.

Electrospray mass spectrometry

INS
A7
Mass spectrometric data regarding tryptic peptides from in-gel digestions were obtained from collision induced dissociation (CID) spectra with a Finnigan-MAT LCQ ion trap mass spectrometer after introduction via a polyamide coated fused silica microcapillary HPLC.

5 Immunoblot Analysis of Cytokeratin 1 and Annexin I

Two 2D gels were run simultaneously, both containing identical amounts of lysates of microdissected tumor from case #1. One gel was silver stained and the other was immunoblotted to PVDF membrane as outlined above. 2D western blot analysis was performed as described earlier except antibody to type II cytokeratin or annexin I was used as probe. Anti-pan type II cytokeratin antibody was purchased from SIGMA and used at a final dilution of 1:1000. Anti-annexin I antibody was purchased from Transduction Labs and used at a final dilution of 1:5000.

Tissue Fixation/Embedding

A male BALB C mouse was sacrificed with immediate surgical excision of the liver. One piece was embedded in OCT compound (Tissue Tek, Miles, Elkhart, IN) and immediately frozen on dry ice. Two pieces were fixed in 70% ethanol containing proteinase inhibitor (Complete, Mini Boehringer Mannheim Corp., Indianapolis, IN) for 1 hour at room temperature. One of these pieces was then embedded and blocked in paraffin wax and the other in polyester wax (Gallard-Schlesinger Industries, Inc., Carle Place, NY). For the polyester wax embedding the tissue was dehydrated in 90% ethanol at 4° C for 1 hour followed by 99% ethanol at 4° C for 1 hour, then by 100% ethanol at room temperature for 1 hour. Then the tissue was infiltrated with 50% polyester wax:ethanol at 42° C for 2 hours followed by 90% polyester wax: ethanol for one hour at 42° C. Finally, the tissue is blocked with 90% polyester wax:ethanol in a cryomold on ice. A separate piece of liver was fixed in 10% neutral buffered formalin and embedded and blocked in paraffin wax. Eight micron thick sections were cut from each of the blocks onto glass slides, stained with hematoxylin and eosin, and approximately 5000 cells (1200 laser pulses) were dissected by LCM. The transfer cap with attached cells was applied to an Eppendorf tube containing 30 microliters of SDS buffer to lyse the cells, and the recovered protein analyzed by SDS-PAGE.

Protein Profiles of Matched Normal and Tumor Esophageal Cells

Protein profiles from microdissected normal epithelium and tumor cells from two patients were analyzed by 2D PAGE (Figure 6). For the purposes of this study proteins were scored as "altered" only if there was a clear-cut "on-off" difference between the comparison groups. No quantitative evaluation was made of the level of those proteins which were present in both sample groups and showed subtle differences in levels. Immunoblot analysis of alpha-tubulin using a small aliquot of each sample was used to verify that equal amounts of total protein were analyzed from each dissection (Figure 6C).

The overall protein profiles between the normal-tumor pairs were highly similar. For example, the microdissected normal epithelium from case #1 shared 98% of the observed proteins with the corresponding tumor (Table 2).

Table 2

	# Protein Alterations
Case #1 Normal epithelium vs. Case #1 Tumor	15 (2%)
Case #2 Normal epithelium vs. Case #2 Tumor	14(2%)
Case #1 Normal epithelium vs. Case #1 Stroma	525 (78%)

However, seventeen distinct differences were observed between the paired normal-tumor samples, 12 of which occurred identically in both cases. The circled spots in panels A and B of Figure 8 show proteins which are either up or down-regulated in each tumor as compared to the matching normal epithelium. As a control to assess inherent 2D PAGE variability each experiment was performed twice and the results compared. One hundred percent of proteins were scored as identical in each duplicate run (results not shown).

Protein Identification

Two proteins, one overexpressed and the other underexpressed in both tumors, were selected for further analysis to determine the feasibility of obtaining identification of proteins derived from microdissected cells. Spots on the 2D gel marked were chosen for mass spectrometry MS-MS sequencing. A second 2D PAGE gel was run except the gel was stained and analyzed with

zinc-imidazole followed by protein elution and in-gel digestion with trypsin. The volume ratio of trypsin to gel plug was strictly controlled to maximize digestion. In addition, the volatile salt ammonium bicarbonate in the digestion buffer was mostly removed before the samples were used without purification to obtain molecular weights by ESI-MS. For each sample, the peptide mass peaks in the ESI-MS spectra were easily distinguished by the impurities and the masses were corrected by using internal calibration standard. With the protocols used in sample handling and MALDI or ESI loading, a large number of authentic peptide mass peaks were present and this made identification by peptide matching computer programs straight forward and very reliable. The results are reported in Table 3. By matching the experimental molecular weights of trypsin digestion products with theoretical predictions, multiple peptides were identified for each of the two proteins, spanning broad regions of the primary amino acid sequence. The protein overexpressed in tumor was identified as cytokeratin 1, and the protein underexpressed in tumors was identified as annexin I.

Table 3

Protein Identity	Mass Found	Mass Calculated	Residues
Keratin I	1265.0	1265.63	278-288
	1358.2	1357.7	444-455
	1476.06	1475.75	212-223
	1717.94	1716.85	418-432
Annexin I	1702.88	1703.6	128-143
	1605.96	1607.54	98-112
	1550.82	1551.46	214-227
	1387.76	1388.00	58-70

Protein Confirmation - Immunoblot

To confirm the mass spectrometry results, microdissected normal epithelium and tumor samples from case #2 were subjected to 2D PAGE separation and immunoblot analysis using an antibody directed against a human pan-type II cytokeratin, and an antibody against annexin I.

- 5 Figure 7 shows the results confirming the identity of the protein up-regulated in tumor as cytokeratin 1. The identity of the protein down-regulated in tumor as annexin I was similarly confirmed (results not shown).

Epithelium vs. Stroma

- 10 To ensure the present approach is efficient at detecting protein alterations between microdissected cell populations a region of stroma was microdissected and compared to dissected normal epithelium and tumor (Figure 8). Stroma cells represent a lineage and phenotype markedly distinct from epithelium. Less than 25% (approximately 150 of 675) of the observed proteins were scored as identical between the two populations (Table 2). None of the 17 proteins which were altered in the normal epithelium-tumor comparisons were present in the stroma.

15 **Whole Tissue Sections vs. Microdissected Cells**

- Samples from whole tissue sections prepared without dissection were analyzed by 2D PAGE and compared to microdissected normal epithelial and tumor cell populations from the same section. The experiment was performed to assess the impact of potential laser capture microdissection induced modifications, such as protein oxidation and proteolysis on 2D PAGE fingerprints. It also determined the percentage of proteins present in a microdissected cell population which could be reliably identified in the whole tissue section from which they were derived. Figure 9 shows the 2D PAGE comparison of the undissected whole tissue section and corresponding microdissected samples. All of the proteins in the 2D gel from the microdissected cells, including those found to be differentially regulated in the tumor (circled), were visualized at the same Mr and pI in the undissected whole tissue section indicating LCM had no apparent effect on proteins recovered from microdissected cells.
- 25

Validation and Extension to Other Cancers

These same methods have been used on eight additional normal/squamous cell cancer of the esophagus cells sets. The results indicated that annexin I is absent in all carcinoma cells, but strongly present in the normal epithelium. Immunohistochemistry experiments, as described above, indicate that annexin I abruptly disappears in this cancer at the pre-malignant state, and continues to be absent as the cells become cancerous. The presently described techniques have also been extended to examine a possible role of annexin I in cancers other than those of the esophagus. In particular, experiments were performed to determine if the level of annexin I was altered in prostate cancer. Using Western blot analysis and immunohistochemical assays, as described above, 2 of the 3 prostate cancers were found to have completely lost the expression of annexin I, while the third cancer had reduced expression. Thus, these results indicate the applicability of the present techniques to the elucidation of protein alterations in a variety of cancer types and other biological conditions (such as normal organ development).

Previous studies of microdissected cell populations have focused primarily on DNA and more recently on analyses of messenger RNA, and have been aimed at identifying gross genomic alterations, specific genes with mutations, or mRNA levels. While these efforts have been successful and hold great promise for identifying molecular profiles in normal and diseased cells, they provide only partial information regarding the protein products of mutated or dysregulated genes. Efficiency of translation, post-translational modifications, protein stability, phosphorylation state, protein-protein interactions, and protein DNA-binding affinities are examples of parameters which cannot be studied by DNA and mRNA efforts alone. Protein-based analyses are required to address these questions. Moreover, protein profiling may more easily detect certain types of alterations than genomic or expression-based approaches, for example, a tumor suppresser gene mutation which results in protein truncation. Therefore, high-throughput protein studies will be an important component of future efforts to determine the molecular anatomy of normal and diseased cells.

Precise recovery of specific cell populations from human tissue is technically challenging, particularly when downstream molecular applications require on the order of tens of thousands of

cells. In this study, procurement of normal epithelium was the most difficult challenge. LCM-based microdissection was critical and allowed recovery of 50,000 normal epithelial (and tumor cells) with a high degree of purity in a reasonably short period of time and did not appear to damage or degrade proteins. Fifty thousand microdissected cells revealed approximately 675 distinct proteins as visualized by 2D-PAGE stained with silver. Assuming the lower limit of detection to be one nanogram, the analysis identified proteins in the abundance range of 50,000 to 1,000,000 copies per cell.

Dysregulated proteins of high or moderate abundance will have sustained utility for basic research and clinical applications as they will be the easiest to detect, study, and monitor. However, proteomic studies of microdissected normal and tumor cells will also benefit from increased sensitivity enabling a larger percentage of the cellular proteins to be analyzed. Additionally, there are many microscopic, biologically interesting (and potentially clinically important) lesions which consist of less than 50,000 cells. In these circumstances, protein labeling with (for example) 125-I labeling or biotinylation dramatically increases the number of proteins visualized from microdissected cells (data not shown). Similarly, scanning immunoblotting with class-specific antibodies allows for more sensitive detection of specific subsets of proteins, for example, all known proteins involved with cell cycle regulation.

In some circumstances, the small amount of material analyzed is not ideal for obtaining highly sensitive protein fingerprints, and identifying proteins of interest. In such circumstances, a useful strategy is to produce parallel "diagnostic" and "sequencing" 2D gels from each case. The diagnostic fingerprints are derived from microdissected cells and provide maximal sensitivity for detection of normal-tumor differences. Sequencing fingerprints then allow for determination of protein identity. The sequencing 2D gels are generated from serial, whole tissue section cryostat recuts which contain abundant amounts of protein representing all cell types present in the tissue, including the dissected cell population(s). Alignment of the diagnostic and sequencing 2D gels permits determination of proteins of interest for subsequent mass spectrometry or N-terminal sequence analysis. This technique successfully visualized and aligned all 675 proteins present in the microdissected tumor cells from case #1 in the corresponding whole tissue section 2D gel. Two

of the tumor-specific alterations were selected for subsequent mass spectrometry and identified as cytokeratin I (overexpressed) and annexin I (underexpressed). The identity of both proteins was confirmed by immunoblot. Consistent with this result cytokeratins and annexin I have been previously reported to be dysregulated in epithelial tumors.

5 It is therefore advantageous, in some embodiments, to compare matched normal and tumor cells from the same patient. Of the seven proteins found to be down-regulated in the tumor, two were observed uniquely in the normal epithelium of case #1, and one was present uniquely in case #2. These proteins are "patient-specific" and would not have been identified if a single reference normal sample had been used as comparator for the tumors. Therefore, direct intrapatient
10 comparison of normal-tumor pairs is advantageous to ensure detection of all protein alterations which occur during tumorigenesis. Moreover, since little is known of the similarities and differences in protein profiles from person to person, the present invention can be used to provide interpatient analyses of both normal and diseased cells to help reveal patient-unique protein profiles related to disease susceptibility or progression.

15 The esophageal specimens utilized in this study were frozen in liquid nitrogen shortly after surgical resection and histologic tissue sections were prepared on a cryostat. Frozen sections are often used for molecular analyses of tissue due to the relatively high quality DNA, RNA, and proteins which can be recovered. Tissue processed through standard formalin fixation and paraffin embedding is less advantageous due to the molecular cross-linking which occurs during fixation and
20 the prolonged exposure to elevated temperatures during embedding.

 In summary, 2D-PAGE protein profiles and subsequent determination of the identity of selected proteins is possible from microdissected cell populations, and is uniquely capable of detecting disease-specific alterations. These techniques and methodologies can determine the abundance and status of proteins *in vivo* for studying normal cells and their associated pathologies.

EXAMPLE 3**Comparative Protein Analysis of Normal and Cancerous Prostate Epithelium and *In Vitro* Prostate Cell Lines**

5

Patients and Tissue Samples

WWS
A8

Tissue from prostate cancer patients undergoing radical prostatectomy at the Clinical Center of the National Cancer Institute (Bethesda, MD) and at the Mayo Clinic (Rochester, MN) was used. Tissue from the peripheral zone of the prostate was procured, immediately snap frozen, and stored at -80° C. Matching normal and tumor cell lines were prepared from the prostatectomy specimen obtain at the NCI and immortalized as described by Bright et al., Cancer Res. 57: 995-1002 (1997). LnCaP and PC3 cells were purchased from the American Type Culture Collection (Manassas, VA). Microdissection was performed and the cells were prepared for 2D-PAGE analysis as described above in Example 2. 2D-PAGE gels were done using alpha-tubulin to normalize the sample load, as described in Example 2. The anti-alpha tubulin antibodies, used at 1:1000, and HRP-coupled rabbit anti-mouse secondary antibodies, used at 1:10,000) were purchased from Sigma (St. Louis, MO). Blots were washed using conditions described above and ECL substrate (Amersham, Piscataway, NJ) was added for chemiluminescent detection via autoradiography on Kodak Bio-Max film. For PSA, anti-PSA antibodies were purchased from Scripps Laboratories, San Diego, CA).

Protein Profiles of Matched Normal and Tumor Prostate Epithelial Cells Analysis of the microdissected cells from two different cases revealed approximately 750 distinct proteins as shown by silver staining. Altered proteins were scored as discussed in Example 2 and the results are reported in Table 4. Twelve total proteins were altered between the normal and tumor prostate tissue. Six tumor specific alterations were present in both cases. Two proteins were exclusively expressed in the normal cells of both cases. Three other proteins were uniquely expressed by normal cells from one case, while an additional protein was uniquely expressed by normal cells in the other case. These results confirm the ability of the present methods to make meaningful comparisons between the protein content of microdissected cell samples. Other proteins were

overexpressed in the cancerous cells, one of which was confirmed by immunoblot to be PSA.

Comparison was also made between epithelial and stromal cells, where less than 45% of the proteins were shared. This result confirms that protein expression differs between epithelium and stroma cell types in various tissue types. The six altered proteins in the epithelial cells were all epithelial specific, indicating that the alterations seen were not due to contamination of the normal cells with stromal cell populations.

Table 4

	# Protein Alterations
Normal prostate epithelium vs. tumor	12 (1.6%)
Normal prostate epithelium vs. normal stroma	412(45%)

Comparison to Prostate Cell Line Protein Expression

To determine if the protein profiles from prostate cancer cell lines are representative of prostate cancer in vivo, lysates of cells cultured in vitro were subjected to 2D-PAGE and the resulting patterns compared to those of LCM-derived normal malignant prostatic epithelium. The 2D-PAGE pattern of two common cell lines, LnCaP and PC3, were first compared to the pattern of in vivo cancerous cells. Protein expression between the two cell lines was similar, but markedly different from the protein profiles of epithelium in vivo, exhibiting less than 20% identity. To assess whether differences in 2D-PAGE profiles were the result of qualitative or quantitative alterations in expression, immunoblots were done using PSA as a test molecule. PSA was not detected in normal cells, PC3, or a tumor cell line developed from the in vivo dissected tumor cells. In contrast, LnCaP expressed PSA, but there was an alteration in the migration, reflective of a change in the qualitative change in the protein. These results indicate that there are both quantitative and qualitative changes in cell expression when comparing immortal and in vivo isolated cells. Finally, a direct comparison between the in vivo tumor cells pre-immortalization and a cell line developed from those tumor cells shows substantial alterations in protein expression. This observation means at least some of the differences in protein expression seen between the LnCaP and PC3 cell lines and the tumor cells reflect of changes in protein expression due to the immortalization process.

EXAMPLE 4**Characterization of PSA Proteins in Tumor and Nontumor Cell Samples****5 LCM of benign and malignant epithelium**

1
10
15
Frozen tissue was obtained from radical prostatectomy specimens and embedded in OCT compound (Tissue-Tek, Miles, Elkhart, IN). Eight micron sections were made with a standard cryostat and stained with hemotoxylin and eosin using standard protocols. Benign and malignant histology was identified by a pathologist and LCM was performed to obtain cells from each population by directing the laser at those populations of cells. LCM was performed as previously described, except AEBSE (Boeringer Mannheim) was added to the staining baths at a final concentration of 2 mM to inhibit proteases. For 1-dimensional and 2-dimensional electrophoresis analysis 2,000 (approximately 8 - 10,000 cells) and 5,000 (approximately 20 - 25,000 cells) 30 micron laser shots of each cell population were used, respectively. Based on careful review of histologic sections each dissection is estimated to contain > 95% of desired cells.

Western blot analysis of intracellular PSA

For 1D PAGE analysis, 2X SDS buffer was used to lyse cells directly from the EVA film (from the LCM cap) and the lysates were run on 20% tris-glycine nondenaturing gels and transferred to a nylon membrane using the Novex system. A murine monoclonal antibody
20 purchased from Scripps Laboratories was used as the primary antibody at a concentration of 1:1,000 and a murine horseradish peroxidase tagged antiIgG antibody from Sigma was used as the secondary antibody. The ECL reaction was generated by the ultra-ECL from Pierce. Purified free PSA and PSA bound to ACT purchased from Scripps were used as controls. For 2-dimensional electrophoresis (2D PAGE), IEF buffer (7M Urea, 2M Thiourea, 4% CHAPS, 1% MEGA-10, 1%
25 Octyl- β -Glucopyranoside, 40 mM Tris, 50 mM DTT, and 2 mM tri-butyl phosphine (TBP) and 0.5% (v/v) Pharmalytes) was used to lyse cells off the EVA fill and the lysates were used to swell pre-cast immobilized pH gradient strips (18 cm, 3-10 non-linear from Pharmacia) overnight. First dimensional separation was performed for a total focusing time of 120 kVh. The strips were re-equilibrated with a solution containing SDS and Tris PH 6.9, reduced with DTT (50 mM),

alkylated with iodoacetamide (2.5% w/v), and directly applied to a 9% isocratic SDS-PAGE gel for electrophoresis overnight at 40 volts constant voltage. The protein was transferred to a nylon membrane and western blot performed using previously described reagents. Twenty 8 micron cryostat sections containing both malignant and benign epithelium were suspended in EF buffer and analyzed by 2D PAGE and western blotting as just described.

PSA/ACT binding studies.

Malignant and normal prostatic epithelium were dissected using LCM and lysis buffer (containing protease inhibitors and 100 mM NaCl) was used to lyse the cells off of the EVA film and solubilize the protein. One microgram of purified ACT (purchased from Scripps) was added to 10ul of lysis buffer containing 2,000 laser shots (approximately 10,000 cells) of normal or malignant epithelium and incubated for 2 hours at 37°C.

Results

PSA is a serine protease that is produced as an inactive zymogen and then activated by release of a signal peptide of 17 amino acids followed by liberation of a 7 amino acid propeptide. The catalytically active form of PSA is highly glycosylated with a molecular mass of approximately 30 kd. Although it has been shown that PSA is constitutively produced in LnCaP cells, the relative proportion of pre and processed forms of PSA within uncultured prostatic epithelium has not been reported. Furthermore, the site at which PSA binds to ACT is also not known. In order to answer these questions, anti-PSA western blot analysis was performed on cellular lysates from LCM derived normal and malignant epithelial cells, which revealed a band at 30kd (Figure 10). These results were highly reproducible in several cases and demonstrate that a majority of intracellular PSA exists as a 30 kd form. This finding suggests that PSA binds to ACT within either the extracellular space or the serum and not intracellularly. The total abundance of cellular PSA varied such that in some cases the malignant cells contained more PSA while in other cases the benign cells contained more PSA. This variability of intracellular PSA levels within both normal and malignant prostatic epithelium is consistent with previous reports.

Binding Experiments

1 To ascertain whether the 30 kd protein represents the active form of PSA we performed experiments to determine if it would bind to ACT. As shown in Figure 11, the majority of cellular PSA complexed with ACT after 2 hours of incubation and there was no difference in the binding capacity of PSA derived from normal and malignant epithelium. This finding suggests that the 30

5 kd form represents active PSA but does not explain why serum percent free PSA is lower in men with cancer. Although the PSA found intracellularly in normal and malignant epithelial cells appeared identical by molecular weight and ACT binding capacity, other protein modifications that do not alter patterns on 1D PAGE gels may have been missed by this investigative methodology.

10 Therefore, 2D PAGE was performed on cellular lysates from LCM derived tissue. As can be seen in Figure 12A, three distinct 30 kd PSA isoforms similarly exist in benign and malignant epithelial cells indicating that the PSA found in malignant prostatic epithelium is not mutated or differentially glycosylated, because this would be reflected in a change in isoelectric focusing point on a 2D Western. Furthermore, none of these three isoforms are a proteolytically cleaved form of PSA

15 since all remained intact under reducing conditions. The fact that the purified PSA/ACT complex remains intact under the reducing conditions (Figure 12B) validates that the findings demonstrated in Figure 11 are not an artifact of 2D PAGE. In addition, whole tissue frozen sections were analyzed (that had not been exposed to LCM) containing both benign and malignant epithelium to demonstrate that firing the laser on the cells did not alter PSA structure (Figure 12A).

20 These experiments show that PSA made in normal and malignant prostatic epithelium does not differ in regards to molecular weight, iso-electric focusing point or ability to bind ACT, and that differences in serum percent free PSA levels are not the result of altered ACT production by malignant prostatic epithelium.

EXAMPLE 5**Production of SELDI Protein Fingerprints for Tumor and Nontumor Cell Samples**

1 To assess the reproducibility of the protein fingerprint generated by SELDI, two separate cell populations of prostatic tumor epithelial cells (1200 cells per dissection) from the same patient

(Case 1) were separately microdissected (Microdissections 1 and 2) from frozen tissue sections. AEBSF (Boeringer Mannheim) was added to the staining baths at a final concentration of 2 mM to inhibit proteases. Based on careful review of the histologic sections by a pathologist, each microdissection was estimated to have greater than 95% purity. Microdissected cells were lysed directly on an LCM cap with 2 μ l of an extraction buffer containing 1% (w/v) Triton-X-100 (Sigma, St. Louis, MO), 1% (w/v) MEGA 10 (ICN, Aurora, OH), and 1% (w/v) octyl-B-glucopyranoside (ESA, Chelmsford, MA) in a standard 1X PBS base. SELDI analysis was performed using an aliphatic reverse phase chip (Ciphergen, Palo Alto, CA.). The bait surfaces on the chip were pretreated with 2 μ l of acetonitrile (Sigma, St. Louis, MO). Shortly before the acetonitrile completely evaporated, 2 μ l of the lysate was applied to the bait surface. The analyte was allowed to concentrate by air drying followed by the application of 0.3 ml of 3,5-dimethoxy-4-hydroxycinnamic acid (sinapinic acid, 98%, Sigma, St. Louis, MO) as the energy absorbing molecule of choice for all experiments in this study.

The results of this experiment (Figure 13A) are displayed in two of several possible formats offered by the SELDI software analysis package. The first representation is a standard chromatographic mass map with the respective molecular weight range displayed on the x-axis. Each "peak" represents a protein isoform with a different molecular weight. The second representation is a Gel-View[®] display which takes the peak data from the mass-map chromatogram and presents the data as if one is looking at a standard 1D PAGE gel "stained" for proteins, with the molecular weight ranges displayed at the same scale as that seen in the chromatogram. The protein profiles of the lysates of separate microdissected regions of the same tumor are nearly identical. These results indicate that reproducible protein profiles are generated from LCM-derived cells. Similar experiments were repeated several times with identical results (data not shown).

To assess the reproducibility and relative homogeneity of captured cell populations of the same cell type between patients, prostatic tumor epithelium from two different patients (Case 1 and Case 2) was dissected (1200 cells per dissection) and analyzed as above. These results are shown by both massmapping and Gel-View[™] display in Figure 13B, and show that the protein fingerprint generated from case 1 and case 2 is highly reproducible. Similar results were obtained with

multiple samples from the two cases (data not shown). The minor differences in protein expression patterns observed between case 1 and case 2 were no more variable than that seen between microdissections from the same case (data not shown).

To assess the relative sensitivity of the SELDI instrument in the detection of protein profiles from LCM-acquired cells, four separate microdissections of decreasing numbers of prostatic tumor epithelium were isolated and the resulting lysate subjected to SELDI analysis using the reverse-phase aliphatic chip as above. The results shown in Figure 13C in Gel-View™ display, indicate that a protein profile from as little as 450 cells can be visualized, and that the spectra is comparable to that seen from 1500 cells. The mass maps from fewer numbers of cells (300 and 150) gave less reproducible results, reflecting microheterogeneity in protein expression from region to region in the same tissue section, or indicating that such lower numbers of cells may not provide the most optimal results when assessing complex protein mixtures from small numbers of cells (data not shown). As a control for each experiment, lysing buffer alone, or LCM with a blank glass slide were analyzed. Each produced a flat baseline SELDI spectra (data not shown). The Gel-View® display normalizes the relative intensities of each separate spectra and does not reflect what was seen in the mass map; that is, as the total number of cells decreases, so does the relative intensity of the peaks seen (data not shown). The results using a range of cell numbers indicate that the relative intensity of the peaks may be proportional to the number of cells, the relative fidelity of the spectra is not altered when studying the protein fingerprints of 450 cells to 1500 cells.

For the purposes of these studies only the molecular weight range of 15 kDa to 70 kDa were analyzed, although the SELDI has a practical resolution and detection working range of 1000 to 300,000 daltons depending on the energy absorbing molecule utilized and the bait surface/wash conditions employed. Western blot analysis of LCM derived cells in our laboratory using anti alpha-tubulin as a housekeeping marker for a protein expression reference standard indicated that procurement of cells by an equal number of laser shots generates a nearly equivalent (+/- 5%) final protein yield (data not shown).

20220729 09:56:50

A14 20

Discriminatory SELDI analysis of different tumor types

A practical application for both clinical and research studies utilizing SELDI fingerprinting of LCM-acquired cell populations would be to develop diagnostic fingerprints which are disease-specific and organ-specific. To assess the feasibility of this concept, we tested the ability of SELDI to discriminate between tumor epithelium from prostate, breast and colon tumors from different patients. Twelve-hundred cells were analyzed as described above, and the resultant spectra are shown in Figure 14A and B. Each tumor type shows a unique fingerprint, illustrating the wide range of protein differences that occur in epithelial cells from different solid tumors types. Novel insights into the protein expression patterns between different types of tumors could aid in the development of new treatment strategies, or the choice of the best strategy. Diagnosis and prognosis from the limiting amounts of cells generated by fine needle aspirants or sentinel node analysis could be achieved very rapidly if a tumor-specific or grade-specific profiles could be generated and used as a template.

SELDI protein fingerprinting of colon cancer with liver metastasis

The ability to assess changes in protein expression occurring during tumor progression will aid in the elucidation of the fundamental mechanisms underlying carcinogenesis in patients. To investigate the potential of SELDI analysis of LCM derived cells to study this process, we analyzed the colonic normal epithelium, primary cancer, and hepatic metastasis from one patient. As a comparison, we analyzed the normal liver cells, which were microdissected from the same case. The results are shown in Figure 14C, and show that a normal epithelial cell and tumor epithelial cell-specific fingerprint can be identified.

Additionally, the protein profile from the colon tumor that had metastasized resembles the colonic epithelium, regardless of tumor or normal cell state, and not the liver cell protein profile. Importantly, the cells from the metastasis have their own distinct protein fingerprint. This uniqueness may arise from the fact that the metastatic tumor has changed its expression profile as a result of its new environment, or it may reflect protein expression changes that enabled the cells to metastasize, or a combination of both. A direct application of this type of analysis would be to identify protein profiles of primary tumors which predict that a tumor has likely metastasized

indicating a need for more aggressive patient treatment and follow-up. If the protein fingerprint from the colon to liver metastasis is compared to the fingerprints of the prostate or breast tumor epithelium (Figure 14A), one can see that the fingerprint most closely resembles that of the colon, regardless of normal or tumor status. A practical application of this type of analysis would be the generation of protein fingerprints that are organ-specific so that metastasis of unknown origin could be characterized and matched to a particular organ type. See Figure 15 for an example of a battery of fingerprints that could be used.

These results indicate that SELDI analysis of LCM-derived cells can be achieved with a high degree of reproducibility, fidelity, sensitivity and discrimination. These operating conditions allow for the exciting possibility of proteomic analysis of small populations of diseased cells directly from patient tissue. We were able to, for the first time, visualize disease-specific protein changes occurring in defined patient-matched cells directly from tissue sections.

Evaluation of Cancer Disease Progression

Normal, pre-malignant prostatic intraepithelial neoplasia (PIN) and frankly invasive cancer cells and normal cells were microdissected from one stained human tissue section and a protein biomarker fingerprint obtained, as discussed above. The comparisons were made between proteins isolated from approximately 1500 cells and all samples were run in triplicate. Two proteins, having molecular weights of 28,000 and 32,000 Daltons, were found to be reproducibly differentially expressed during the progression of the cells from normal to pre-cancerous to frankly invasive. The results are disclosed in Figure 17A, 17B, and 17C. In particular, the relative ratio of expression of these two proteins can be correlated to the state of the cell and is reproducible in the three cases analyzed. Although this is an extremely small sample set, this experiment does demonstrate the ability of the present techniques to analysis of the progression of a cell sample to cancer.

Extension to Other Cancers

These same methods have been extended to determine the presence of protein "biomarkers" in eight normal/squamous cell cancer of the esophagus cell sets. Three separate independent microdissections of eight different patients' tumor and normal esophageal epithelium

10

Multiplexed Tissue Arrays for High-Throughput Target Validation and Drug-Tissue Interaction Assay

15

25

To apply the present methods to this type of analysis, the tissue from multiple patients is exposed to the agent to be tested. The exposure can be done *in vivo*, prior to collection of the sample, or *in vitro*, after collection of the sample and/or after laser microdissection. *In vivo* exposure would involve administration of the agent to the subject, while *in vitro* administration could be administration to cultured cells. Some agents that could be tested include pharmacological agents, imaging agents, labeled proteins, such as ligands, or other agents known to have particular

effects on cells, such as cytokines. After exposure, microdissection techniques are used to isolate the cells of interest from the sample, the cells are lysed to allow isolation of the proteins or other cellular components, such as nucleic acids or other subcellular structures, from the sample, and the lysate contents are transferred to a confined zone of a substrate. The lysate contents, or cellular components, are placed in identifiable positions on a substrate, where such positions are confined zones. One example of a confined zone is the coordinates of an array. The array is constructed by applying microspots of the isolated proteins on any suitable matrix, such as nitrocellulose, nylon, or silica.

Referring to Figure 19, the microspots are arranged on the matrix in any manner that produces meaningful data. The microspots can be placed on the matrix using, for example, a micropipette, and examples of the substrate include a glass or plastic slide, a section of embedding medium, or a nitrocellulose matrix. In one embodiment, the microspots can be arranged in the y-dimension by patient number and in the x-dimension by a criterion for categorizing the various samples obtained, such as by stage of malignancy. Other alternative criteria include before and after treatment samples, various cells types, such as epithelial and stromal, or stages of development for embryonic samples. The microspots are then subjected to some type of analysis, for example, to determine if an amount of a particular protein is altered. Such analysis can include probing with an antibody as the binding agent. Alternative analyses include probing with other binding agents such as nucleic acids, labeled or unlabeled DNA or RNA, or aptameric or phage display screening. A consistent alteration in the cellular content of a protein is then correlated to exposure of the tissue or cells to the agent of interest.

The matrix can be a general capture matrix, such that all isolated proteins from the sample are present, or embedded with a specific binding agent that would result in the maintenance of only proteins of interest. In this embodiment, the microdissected proteins in a soluble form can be labeled, for example with a radioactive or fluorescent tag, and capture by the binding agent is detected by the presence of the label. Alternatively, the protein spots themselves can act as a binding agent or attractant for an interaction, such as detection of a labeled target or ligand within the protein spot after treatment with a labeled test solution. Because of the method of isolation of

the proteins, the test is highly sensitive, as each spot may be the protein extracted from a pure population of cells from an individual tissue, or a combination of particular populations of interest.

By using samples from multiple patients, the results have greater statistical significance.

Alternatively, a large number of samples can be gathered from one patient's tissue or tissues to
5 achieve the desired statistical results. Other sample sources besides patient tissue include formalin and ethanol fixed paraffin embedded stained tissue sections. With such a sample, it is possible to view the stained tissue using microscopy, then microdissect cells from the precise area of the slide of interest for further analysis. The results can then be referenced back to photographs or other records of the slide image.

10 Additionally, it is anticipated that the tissue arrays can include a body tissue set, which allows comparison of the results obtained from the experimental tissue set to samples from other tissues of the patient's body. Thus, any variation in individual patient protein composition, or any global effect a therapeutic may have, can be taken into account during interpretation of the results. Other possible controls include known protein mixtures applied to the matrix in spots or "spiking"
15 each spot with a positive control.

A schematic drawing illustrating a sample tissue array for examining protein content of breast tissue of multiple patients is illustrated in Figure 19. In this illustration, the tissue from multiple patients is used to examine the effect of a particular therapeutic agent administered to a subject on protein content of breast tissue in various stages of malignancy, from normal tissue to
20 stromal invasion. These tissues are microdissected from a tissue specimen using LCM. Because of the sensitivity of the test, detailed questions about effects on the level of cellular biochemical pathways in each stage subset can be obtained.

An additional application of tissue array technology to the methods of the present invention is the use of the protein content assay to prescreen various tissue types for the target of diagnostic
25 or therapeutic moieties. In this embodiment, a therapeutic or diagnostic agent is being evaluated for its appropriateness in a patient's treatment. If the target of this agent is known, the presence or absence of this target in various cell types of the patient can be tested. Thus, using the breast tissue of Figure 19 as an example, if it was questionable whether a target enzyme for a chemotherapeutic

agent was present in a particular patient's cancerous cells, the samples are generated and placed in an array as illustrated. Then an antibody or other means of identification of the target is used to determine if the target agent is present. This allows diagnostic, imaging, or therapeutic agents to be specifically selected for patients or disease types based on the presence of the target molecule in the diseased tissue.

To prepare a comparison assay between a tissue sample and the results of an array analysis, tissue may, for example, be preserved by fixation in 70% ethanol and embedded in a paraffin block. The paraffin block is cut in 5 to 10 μm sections and mounted on microscope slides. The tissue on these slides is deparaffinized by placing the slide in room temperature xylene for 5 minutes, followed by xylene heated to 70°C for 5 minutes. The slide is next placed in acetone for 10 seconds, Diff Quick Solution II (Dade Behringer) for 5 seconds, and acetone for 10 seconds. The stained slide is allowed to rinse in xylene for a minimum of 30 seconds to dehydrate.

Cells of interest are dissected from the slide by LCM using the PixCell II (Arcturus Engineering). Using the 30 μm spot size, 3000 laser pulses are fired to collect cells from a subcellular structure of interest, and the cells are embedded in a thermoplastic polymer film supported on a plastic cap. An extraction buffer consisting of one part SDS sample buffer (Novex) with 4% BME and one part T-PER (Pierce) is heated to boiling. A 40 μl aliquot of the hot extraction buffer is added to a standard 500 μl microcentrifuge tube. The cap containing the tissue embedded on the thermoplastic film is inserted into the tube and inverted to allow the extraction buffer to cover the tissue. The inverted tube is vortexed for 20-30 seconds to aid in the disruption of the cells and release of the cellular components. Still inverted, with the buffer flooding the cap surface, the tube and cap assembly is placed in a 70°C incubator for overnight incubation. After the incubation, the tube is once more vortexed in an inverted position, after which it is turned upright and centrifuged for 10 seconds. Dilutions are made from the resulting lysate using T-PER. A minimum of 10 μl of lysate or dilution is placed in the bottom of a well of a 96-well round-bottom microtiter plate.

This plate is positioned on the stage of Genetic Micro Systems 417 Arrayer. Oncyte Slides (Schleicher & Schuell) covered in pure nitrocellulose are placed in the appropriate positions

on the arrayer. After the desired number of slides and replicates has been programmed into the accompanying software, the instrument is activated. A metal micro tube lowers into the appropriate well and lifts 1 μ l of the lysate, trapping it inside the bore of the tube. After positioning the tube over the nitrocellulose slide, a pin pierces the trapped lysate, spotting a minute aliquot onto the nitrocellulose surface measuring 500 μ m in diameter.

Two different detection systems have been used successfully to visualize and quantitate the concentration of the proteins applied to the nitrocellulose and are representative of the detection means that can be used with the methods of the present invention.

10 System One

The Western-Star Chemiluminescent Detection System (TROPIX, Inc., Bedford, MA) is an immunoblot detection system designed for membrane-bound proteins. The protocol outlined for nitrocellulose membranes is followed for the Oncyte slides. After the nitrocellulose slide is prepared on the arrayer and dried, it is submerged in I-Block blocking buffer (provided in the kit) prepared as directed, and agitated on an orbital mixer for at least 1 hour. The primary antibody of choice is diluted of the recommended concentration using I-Block buffer. The slides are drained after the blocking step and the diluted primary antibody is poured over the slides and for incubation, with agitation, overnight at 4°C. After the overnight incubation, the slides are washed with agitation in a 1X PBS/0.1% TWEEN washing buffer, one time for 15 minutes and twice for 5 minutes. The secondary antibody which is conjugated to alkaline phosphatase is diluted in I-Block blocking buffer and poured over the slide. It is allowed to incubate for 4-5 hours at room temperature on an orbital mixer. At the end of this incubation, the slide is washed with PBS washing as described above. The 10X Assay Buffer (provided in the kit) is diluted with deionized water and the slide is incubated twice for two minutes submerged in the 1X Assay Buffer. The slides are blotted dry on a piece of tissue paper. For the nitrocellulose slides, a 1:20 dilution of Nitro-Block-II (provided in the kit) is prepared using the CDP-Star Ready-To-Use substrate solution. This substrate solution is pooled on the slide and allowed to sit undisturbed for 5 minutes. At the end of this incubation, the slide is blotted and placed in a plastic development folder, after

which it is exposed to x-ray film. Representative results using this system for analysis of the content of prostate soluble antigen in prostate tissue is shown in Figures 20B and 20C.

System Two

The second illustrative example uses the DAKO Autostainer Universal Staining System (DAKO Corporation, Carpinteria, CA). This automated slide processing system uses a primary antibody followed by the addition of a patented horse-radish peroxidase labeled polymer (DAKO EnVision™ System). This is an example of a colorimetric-detectable labeled antibody. The prepared Oncyte slide is blocked in I-Block (TROPIX, Inc.) for a minimum of 1 hour. The DAKO Autostainer is programmed with the incubation times and volumes of the reagents to be dispensed on the slides. The nitrocellulose slide is washed with a Wash Buffer wash (prepackaged by DAKO). The primary antibody, diluted as specified for the antibody being used, is applied in the predetermined amount of 600 μ l, and allowed to incubate for 30 minutes. At the end of the incubation, the slide is washed with 600 μ l of the Wash Buffer. This step is followed by the addition of the HRP labeled polymer for 10 minutes, followed by washing with the Wash Buffer. The substrate is added to the slide and allowed to sit for 5 minutes, followed by a final wash, and is then allowed to dry for optimal visualization. The positive results are visible staining of the spotted proteins on the slide. Representative results using this system for analysis of the content of prostate soluble antigen (PSA) in prostate tissue are shown in Figure 20A.

The tissue array method for analyzing protein content of small sample sizes is very reproducible, even when applied to very small numbers of cells. Experiments to examine the reproducibility of the technique were done using five separate slides of normal esophageal tissue, and detection for annexin I was performed. The size of the samples varied in the number of microdissection "shots," from a high of 500 shots to a low of 16 shots. Samples of varying cell numbers were collected, the proteins were isolated as described above, and the isolated proteins were placed on a matrix of nitrocellulose paper. Using standard Western techniques, the microspotted proteins were probed using the antibody systems described above. The results of these tests are diagrammed in Figures 21A, 21B, and 21C. Figure 21A indicates that the results from each data set (average of triplicate results for each slide) remains consistent within the set. As

is expected, the amount of variance increases with the smaller number of "shots" included in the sample. However, as indicated graphically in Figure 21B, the results for multiple samples containing as few as 125 shots varies only by 18%. These results indicate that this method of analyzing protein content of small tissue samples is reliable. The results shown in Figure 21C also support this conclusion and indicate that the relative value between the various series remains generally consistent between samples of varying numbers of shots. In summary, the results indicate that decreasing the number of "shots" in a sample affects only the quantitative, not qualitative, character of the results.

Example results of method of present invention where the binding agent has been immobilized, and the cell lysates placed in contact with the immobilized agent are shown in Figure 22. In this experiment, lysates from microdissected normal and tumor esophageal cells were labeled with biotin. An array of binding agents, including anti-annexin I, anti-alpha tubulin, anti-phospho ERK, and mouse IgG1, and normal rabbit serum were placed on nitrocellulose paper. Biotin labeled lysates were placed in contact with the binding agent arrays, and the interaction was detected by avidin-peroxidase. As shown in Figure 22, the tumor lysates contained a reduced concentration of annexin I, and an increased concentration of phospho ERK when compared to the normal cell lysates.

It is understood that the invention is not limited to the specific embodiments shown and described, but changes or modifications can be made in the embodiments without departing from the contemplated scope of the present invention.

SVJ
A17

We claim:

1. A method of analyzing the protein content of a population of cells from a tissue sample, comprising:
- 5 capture microdissection;
- a) extracting the population of cells from the tissue sample using laser
- b) isolating a protein sample from the extracted cell population; and
- c) analyzing the isolated protein sample.
2. The method of claim 1 wherein isolating the protein sample comprises solubilizing the extracted cell contents in a small volume of a buffer comprising at least one
- 10 detergent to solubilize the cellular lipids, at least one proteinase inhibitor to preserve protein content and function, and at least one salt to lyse the nuclear contents.
3. The method of claim 2 wherein the small volume of buffer is about 1 μ l to about 15 μ l.
4. The method of claim 1 wherein analyzing the protein sample comprises
- 15 performing a soluble immunoassay using a labeled antibody specific for a protein of interest.
5. The method of claim 4 wherein the labeled antibody is labeled with a marker selected from the group consisting of colorimetric-detectable, chemiluminescence, fluorescence, and radioactivity.
6. A method of quantifying the amount of a protein of interest in a population of
- 20 cells, comprising:
- a) extracting the population of cells from the tissue sample using laser capture microdissection;
- b) isolating a protein sample from the extracted cell population by solubilizing the extracted cell contents in about 1 μ l to about 15 μ l of a buffer where the buffer
- 25 comprises Tris-HCl, NP-40, sodium deoxycholate, sodium chloride, EDTA, aprotinin, leupeptin, sodium pyrophosphate, sodium orthovanadate, and AEBSF; and
- c) performing a soluble immunoassay using an antibody specific for a protein of interest in the protein sample, where the antibody is labeled with a marker selected from
- SVJ
A18

the group consisting of colorimetric-detectable, chemiluminescence, fluorescence, and radioactivity wherein the assay is calibrated to indicate the amount of the protein of interest present in the cell population.

7. The method of claim 6 wherein the protein of interest is prostate soluble antigen (PSA).

8. The method of claim 1 wherein analyzing the isolated protein sample comprises:
a) performing a one dimensional polyacrylamide gel electrophoresis (1D PAGE) or two dimensional polyacrylamide gel electrophoresis (2D PAGE) to separate proteins from each other; and

b) further analyzing the proteins using a protein specific dye or Western blotting with a labeled antibody specific for the protein of interest.

9. The method of claim 1 wherein analyzing the protein sample comprises
a) performing a two dimensional polyacrylimide gel electrophoresis (2D PAGE) to separate the proteins from each other;

b) isolating a protein of interest from the gel; and

c) determining an amino acid sequence of the protein of interest.

10. The method of claim 9 wherein the sequence is determined using a method selected from the group consisting of N-terminal sequencing, mass spectrometry MS-MS sequencing, liquid chromatography quadrapole ion trap electrospray (LCQ-MS), and matrix assisted laser desorption/time of flight analysis (MALDI/TOF).

11. The method of claim 1 wherein analyzing the protein sample comprises performing surface enhanced laser desorption ionization spectroscopy (SELDI) to produce a protein fingerprint for the cell population.

12. The method of claim 1 wherein the cell population is microscopically identifiable as a tumor cell.

13. A method of characterizing binding properties of one or more intracellular proteins of a population of cells, comprising:

- 5
- a) extracting the population of cells from the tissue sample using laser capture microdissection;
 - b) performing a one dimensional polyacrylimide gel electrophoresis (1D PAGE) or two dimensional polyacrylimide gel electrophoresis (2D PAGE) to separate the proteins from each other;
 - 10 c) removing at least one protein of interest from the gel;
 - d) further analyzing the protein of interest by incubating the protein with a known or putative binding partner for the protein of interest; and
 - e) determining whether the protein of interest binds to the known or putative binding partner.

14. The method of claim 13 wherein the protein of interest is PSA and the known binding partner is alpha-1-antichymotrypsin (ACT).

15. A method of differentiating a protein content of several populations of cells of a tissue sample, comprising the steps of:

- 20
- a) extracting at least a first and a second population of cellular material directly from one or more tissue samples using laser capture microdissection;
 - b) isolating protein from the extracted cell populations;
 - c) analyzing the isolated protein; and
 - d) comparing a protein content of the first cell population to a protein content of the second cell population to identify the differing content.

25 16. The method of claim 15 wherein isolating protein comprises solubilizing the extracted cellular material in a small volume of a buffer wherein the buffer comprises Tris-HCl, NP-40, sodium deoxycholate, sodium chloride, EDTA, aprotinin, leupeptin, sodium pyrophosphate, sodium orthovanadate, and AEBSF.

17. The method of claim 15 wherein the small volume of buffer is about 1 μ l to about

15 μ l.

18. The method of claim 15 wherein analyzing the isolated protein comprises performing a soluble immunoassay using a labeled antibody specific for a protein of interest wherein the assay is calibrated to indicate the amount of the protein of interest present in the cell population.

19. The method of claim 15 wherein the immunoassay is of high sensitivity and the labeled antibody is labeled with a marker selected from the group consisting of colorimetric-detectable, chemiluminescence, fluorescence, and radioactive labels.

20. The method of claim 15 wherein analyzing the isolated protein comprises:

- a) performing a two dimensional polyacrylamide gel electrophoresis (2D PAGE) to separate proteins from each other;
- b) isolating a protein of interest from the gel; and
- c) determining an amino acid sequence of the protein of interest.

21. The method of claim 20 wherein the sequence is determined using a method selected from the group consisting of N-terminal sequencing, mass spectrometry MS-MS sequencing, liquid chromatography quadrupole ion trap electrospray (LCQ-MS), and matrix assisted laser desorption/time of flight analysis (MALDI/TOF).

22. The method of claim 15 wherein analyzing the isolated protein comprises:

- a) performing a one dimensional polyacrylamide gel electrophoresis (1D PAGE) or two dimensional polyacrylamide gel electrophoresis (2D PAGE) to separate protein fractions from each other; and
- b) further analyzing the protein fractions using a protein specific dye or Western blotting with a labeled antibody specific for a protein of interest.

23. The method of claim 15 wherein the first population of cells and the second population of cells are from the same tissue sample and the first population is microscopically identifiable as tumor cells and the second population is microscopically identifiable as normal cells.

24. The method of claim 15 wherein the first population comprises several subpopulations wherein each subpopulation is microscopically identifiable as cells at different stages of tumor progression.

25. A method of comparing the protein content of a first population of cells microscopically identifiable as tumor cells to the protein content of a second population of cells that are normal wherein both populations of cells are extracted from the same tissue sample, the method comprising:

a) extracting the first and second populations of cells from the tissue sample using laser capture microdissection, in which a laser targets the first and second populations as microscopically distinct and separates them from a larger microscopic structure;

b) isolating a protein sample from each extracted cell population by solubilizing the extracted cell contents in about 1 μ l to about 15 μ l of a buffer where the buffer comprises Tris-HCl, NP-40, sodium deoxycholate, sodium chloride, EDTA, aprotinin, leupeptin, sodium pyrophosphate, sodium orthovanadate, and AEBSF; and

c) performing a one dimensional polyacrylamide gel electrophoresis (1D PAGE) or two dimensional polyacrylamide gel electrophoresis (2D PAGE) to separate proteins of the protein sample from each cell population;

d) further analyzing the separated proteins of each cell population using a protein specific dye or Western blotting with a labeled antibody specific for a protein of interest; and

e) comparing a protein of interest content of the first cell population to a protein of interest content of the second cell population.

26. A method of comparing the protein content of a first population of cells microscopically identifiable as tumor cells to the protein content of a second population of cells in order to identify the origin of the first population of cells, the method comprising:

a) extracting the first and second populations of cells from the tissue sample and from each other using laser capture microdissection;

b) isolating a protein sample from each extracted cell population by solubilizing cells from extracted cell populations in about 1 μ l to about 15 μ l of a buffer where the buffer

comprises Tris-HCl, NP-40, sodium deoxycholate, sodium chloride, EDTA, aprotinin, leupeptin, sodium pyrophosphate, sodium orthovanadate, and AEBSF;

c) performing surface enhanced laser desorption ionization spectroscopy (SELDI) to produce a protein fingerprint of the protein sample for each cell population; and

5 d) comparing the protein fingerprint of the first population of cells to the protein fingerprint of a known second population of cells to determine whether or not the two populations have the same origin.

27. The method of claim 26 wherein said first population of cells is microscopically identifiable as a tumor metastasis and the second population of cells is a battery of known normal
10 tissue samples.

28. The method of claim 27 wherein the known normal tissue samples are from the same patient as the first population of cells.

29. A device for isolating protein from a population of cells collected by laser capture microdissection, comprising a chamber in which are present a population of cells obtained by laser
15 microdissection, at least one input port connected to the chamber with a canal having the ability to move liquid introduced into the inlet port by capillary action, a supply of liquid in communication with the inlet port for isolating a protein sample from the population of cells, and at least one output port.

30. The device of claim 29 wherein the chamber is structured to allow the direct
20 acceptance of a cap used to collect cells in the laser capture microdissection process.

31. The device of claim 29 wherein the at least one input port is provided with a means to introduce volumes of liquid into the inlet port and canal.

32. The device of claim 31 wherein said means is a syringe.

33. A device for isolating protein from a population of cells collected by laser capture
25 microdissection, comprising a chamber, three input ports having syringes for the introduction of small volumes of liquid into the chamber, where the input ports are connected to the chamber with canals having the ability to move liquid introduced into the inlet port.

53
A26

34. A method of screening for the presence of a cellular component in a population of cells from a tissue sample, comprising:

- 5
- a) extracting a population of cells from the tissue sample using laser capture microdissection;
 - b) lysing the extracted cell population to produce cellular components;
 - c) immobilizing at least one cellular component or a binding agent in a confined zone;
 - d) contacting the cellular components with the binding agent; and
 - e) detecting the interaction between the components and the binding agent.

10

35. The method of claim 34 wherein the cellular component or the binding agent is labeled, and detecting the interaction between the cellular component and the binding agent comprises detecting the presence of the label.

36. The method of claim 35 wherein the label is detected by a method selected from the group consisting of a colorimetric, chemiluminescent, radioactive, and fluorescent label.

15

37. The method of claim 34 wherein the confined zone of the immobilized cellular component or the immobilized binding agent is an array.

38. The method of claim 34 wherein the cellular component is immobilized.

39. The method of claim 34 wherein the binding agent is immobilized.

40. A method of screening for the presence of a cellular component in a population of cells obtained by laser capture microdissection from a tissue sample, comprising:

20

providing an array that includes either (a) an array of immobilized binding agents for the cellular component or (b) an array of immobilized cellular components from the microdissected cells;

25

exposing the array of immobilized binding agents to laser microdissected cellular components, or exposing the array of immobilized cellular components to binding agents for cellular components of interest.

1/22

FIG. 1A





FIG. 1B



2/22

FIG. 2



3/22

FIG. 3A





FIG. 3B



4/22

Sample	Mean PSA molecules (RLUs)	C.V.%	Mean no. cells
Prostate Tumor 100 shots (n=10)	1.2×10^8 (7,199,673)	3.9 %	721
Prostate Tumor 15 shots (n=10)	1.9×10^7 (1,178,202)	15.8 %	78
Prostate Tumor Single Shot (n=19)	1.8×10^6 (708,730)	54.7 %	6.3
Buffer Control (n=10)	Negative (88,788)	3.5%	NA
Lung 100 shots (n=10)	Negative (134,413)	6.5%	NA
Prostate Stroma 100 shots (n=6)	Negative (132,759)	5.2%	NA




FIG. 4

5/22

Case Designation and Histologic Diagnosis	Molecules of PSA/Cell Mean per 100 shots	Immunohistochemistry Score
Case A Normal		+
	6.66×10^4	
Case B Tumor		+
	9.52×10^4	
Case C Tumor		+
	1.99×10^4	
Case B Normal		++
	1.04×10^5	
Case B PIN		++
	4.25×10^5	
Case C PIN		++
	3.70×10^5	
Case A Tumor		+++
	3.4×10^6	
Case C Normal		+++
	6.3×10^6	


FIG. 5

6/22



7/22

FIG. 7



8/22

FIG. 8

Case #2 Stroma
Silver Stained



Case #2 Tumor Epithelium
Silver Stained





Case #2 Normal Epithelium
Silver Stained




9/22

FIG. 9



Case #2 Normal Epithelium
Silver StainedCase #2 Tumor Epithelium
Silver StainedCase #2 Whole Cryostat
Silver Stained

10/22

FIG. 10



11/22



12/22

FIG. 12A





FIG. 12B



13/22

FIG. 13A




FIG. 13B






FIG. 13C



14/22

FIG. 14A




Prostate Tumor

Breast Tumor

Colon Tumor

FIG. 14B




Prostate Tumor

Breast Tumor

Colon Tumor

FIG. 14C



Colon Normal

Colon Tumor


Colon Metastasis

Liver Normal

15/22


Fingerprint comparison between a variety of
tumor types

FIG. 15



16/22

FIG. 16



17/22





FIG. 18A




FIG. 18B






FIG. 18C



19/22



20/22




FIG. 20A




FIG. 20B




FIG. 20C

FIG. 21A




FIG. 21B





FIG. 21C



22/22




FIG. 22

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 00/04023

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 G01N33/68 G01N1/30 B01L3/00

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 G01N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, BIOSIS

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	SIMONE N L ET AL: "Laser-capture microdissection: opening the microscopic frontier to molecular analysis" TRENDS IN GENETICS,NL,ELSEVIER SCIENCE PUBLISHERS B.V. AMSTERDAM, vol. 14, no. 7, 1 July 1998 (1998-07-01), pages 272-276, XP004124689 ISSN: 0168-9525 figures 2,3	1,8-10, 12,13, 15,17, 20-24
X	US 5 843 657 A (BUCK MICHAEL E ET AL) 1 December 1998 (1998-12-01) cited in the application examples 4,5 column 7, line 51 - line 54 --- -/--	1-5, 8-13,15, 17-24, 35-41

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

28 July 2000

Date of mailing of the international search report

29.11.00

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Hart-Davis, J

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 00/04023

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P,X	<p>BANKS ROSAMONDE E; DUNN MICHAEL J ET AL.: "The potential use of laser capture microdissection to selectively obtain distinct populations of cells for proteomic analysis - Preliminary findings" ELECTROPHORESIS, vol. 20, April 1999 (1999-04) - May 1999 (1999-05), pages 689-700, XP000925546 the whole document</p> <p>---</p>	<p>1-5, 8-13,15, 17-24, 35-41</p>
P,X	<p>SIMONE N L; REMALEY A T; PETRICOIN E F; GLICKMAN J W; BONNER R; EMMERT-BUCK M R; FLEISCHER T A; LIOTTA L A: "PSA quantitation in prostate cancer tissue cells procured by laser capture microdissection" PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH ANNUAL MEETING (90TH ANNUAL MEETING, PHILADELPHIA, PENNSYLVANIA, USA; APRIL 10-14, 1999), vol. 40, March 1999 (1999-03), page 411 XP000929252 abstract</p> <p>---</p>	<p>13,14</p>
P,X	<p>EMMERT-BUCK M R; ORNSTEIN D K; GILLESPIE J W; PAWELETZ C P; VOCKE C D; ET AL.: "Protein fingerprinting of LCM-dissected human esophageal and prostate cancer by 2D-PAGE" PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH ANNUAL MEETING (90TH ANNUAL MEETING, PHILADELPHIA, PENNSYLVANIA, USA; APRIL 10-14, 1999), vol. 40, no. 526, March 1999 (1999-03), page 526 XP000929253 abstract</p> <p>---</p>	<p>13,14</p>
T	<p>EMMERT-BUCK MICHAEL R; GILLESPIE JOHN W ET AL.: "An approach to proteomic analysis of human tumors" MOLECULAR CARCINOGENESIS, vol. 27, March 2000 (2000-03), pages 158-165, XP000925515 the whole document</p> <p>---</p> <p>-/--</p>	<p>1-29, 35-41</p>

INTERNATIONAL SEARCH REPORT

Int'l Application No
PCT/US 00/04023

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
T	CAZARES L H; GONG L; NASIM S; SCHELLMAMMER P F; WRIGHT G L JR: "Discovery of prostate cancer biomarkers from laser capture microdissected (LCM) cells using innovative ProteinChip™ SELDI mass spectroscopy" PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH ANNUAL MEETING (91ST ANNUAL MEETING, SAN FRANCISCO, CALIFORNIA, USA; APRIL 01-05, 2000), March 2000 (2000-03), page 851 XP000929268 abstract	13,14
A	--- US 4 976 957 A (BOGOCH SAMUEL) 11 December 1990 (1990-12-11) examples 1-5	
A	--- DATABASE WPI Week 198703 Derwent Publications Ltd., London, GB; AN 1987-017788 XP002143852 NOGUCHI JUJI ET AL.: "Protein from animal cerebral nerve tumour cell ..." & JP 61 275221 A (MITSUI PHARMACEUT. INC.) , 5 December 1986 (1986-12-05) abstract -----	

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US 00/04023

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

see additional sheet

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☒ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

1-29, 35-41

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. Claims: 1-29,35-41

Methods of analysing proteins or other cellular components involving the extraction of a population of cells from a tissue sample using laser capture microdissection.

2. Claims: 30-34

Devices comprising chambers having at least one input port.

INTERNATIONAL SEARCH REPORT

Information on patent family members

In International Application No
PCT/US 00/04023

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US 5843657 A	01-12-1998	US 5843644 A	01-12-1998
		AU 716979 B	16-03-2000
		AU 7663396 A	30-04-1997
		CA 2233614 A	17-04-1997
		EP 0862612 A	09-09-1998
		JP 2000500325 T	18-01-2000
		WO 9713838 A	17-04-1997
		US 6010888 A	04-01-2000
		AT 182405 T	15-08-1999
		AU 691263 B	14-05-1998
		AU 1933795 A	18-09-1995
		CA 2184245 A	08-09-1995
		CN 1143413 A	19-02-1997
		DE 69510925 D	26-08-1999
		DE 69510925 T	17-02-2000
		EP 0748439 A	18-12-1996
		ES 2138727 T	16-01-2000
		JP 10500205 T	06-01-1998
		WO 9523960 A	08-09-1995

US 4976957 A	11-12-1990	US 4298590 A	03-11-1981
		US 4840915 A	20-06-1989
		AT 8897 T	15-08-1984
		DE 3068844 D	13-09-1984
		EP 0015755 A	17-09-1980
		JP 1514082 C	24-08-1989
		JP 55167265 A	26-12-1980
		JP 63062517 B	02-12-1988
		CA 1057684 A	03-07-1979
		CH 639102 A	31-10-1983
		DE 2606257 A	26-08-1976
		FR 2327798 A	13-05-1977
		GB 1533464 A	22-11-1978
		JP 1046520 B	09-10-1989
		JP 1565629 C	25-06-1990
		JP 51108001 A	25-09-1976
		JP 1112163 A	28-04-1989
		JP 1633581 C	20-01-1992
		JP 2057671 B	05-12-1990
		US 4195017 A	25-03-1980
		US 4196186 A	01-04-1980
		AT 16220 T	15-11-1985
		DE 2967534 D	28-11-1985
		EP 0007214 A	23-01-1980
		HU 185603 B	28-03-1985
		JP 55037989 A	17-03-1980
		US 4486538 A	04-12-1984

JP 61275221 A	05-12-1986	NONE	

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
24 August 2000 (24.08.2000)

PCT

(10) International Publication Number
WO 00/49410 A3

(51) International Patent Classification⁷: G01N 33/68,
1/30, B01L 3/00

(21) International Application Number: PCT/US00/04023

(22) International Filing Date: 16 February 2000 (16.02.2000)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/120,288 16 February 1999 (16.02.1999) US

(71) Applicant (for all designated States except US): THE
GOVERNMENT OF THE UNITED STATES OF
AMERICA, as represented by THE SECRETARY
DEPARTMENT OF HEALTH & HUMAN SER-
VICES, THE NATIONAL INSTITUTES OF HEALTH
[US/US]; Office of Technology Transfer, 6011 Executive
Boulevard, Suite #325, Rockville, MD 20852 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): LIOTTA, Lance,
A. [US/US]; 8601 Bradley Boulevard, Bethesda, MD
20817 (US). SIMONE, Nicole [US/US]; 16 Balsam

Court, Lawrenceville, NJ 08648 (US). EMMERT-BUCK,
Michael [US/US]; 13620 Cedar Creek Lane, Silver
Spring, MD 20904 (US). PETRICOIN, Emmanuel, F.,
III [US/US]; 2805 Feather Ridge Court, Dunkirk, MD
20754 (US).


(74) Agent: NOONAN, William, D.; Klarquist, Sparkman,
Campbell, Leigh & Winston, Leigh, Suite 1600 - One
World Trade Center, 121 SW Salmon Street, Portland, OR
97204 (US).

(81) Designated States (national): AE, AL, AM, AT, AU, AZ,
BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK,
DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL,
IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU,
LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT,
RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA,
UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM,
KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent
(AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent
(AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU,
MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM,
GA, GN, GW, ML, MR, NE, SN, TD, TG).

[Continued on next page]

(54) Title: LCM (LASER CAPTURE MICRODISSECTION) FOR CELLULAR PROTEIN ANALYSIS



(57) Abstract: The present invention describes devices and methods for performing protein analysis on laser capture microdissected cells, which permits proteomic analysis on cells of different populations. Particular disclosed examples are analysis of normal versus malignant cells, or a comparison of differential protein expression in cells that are progressing from normal to malignant. The protein content of the microdissected cells may be analyzed using techniques such as immunoassays, 1D and 2D gel electrophoresis characterization, Western blotting, liquid chromatography quadrupole ion trap electrospray (LCQ-MS), Matrix Assisted Laser Desorption Ionization/Time of Flight (MALDI/TOF), and Surface Enhanced Laser Desorption Ionization Spectroscopy (SELDI). In addition to permitting direct comparison of qualitative and quantitative protein content of tumor cells and normal cells from the same tissue sample, the methods also allow for investigation of protein characteristics of tumor cells, such as binding ability and amino acid sequence, and differential expression of proteins in particular cell populations in response to drug treatment. The present methods also provide, through the use of protein fingerprinting, a rapid and reliable way to identify the source tissue of a tumor metastasis.



(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

(48) Date of publication of this corrected version:

30 August 2001

(15) Information about Correction:

see PCT Gazette No. 35/2001 of 30 August 2001, Section II

Published:

— with international search report

(88) Date of publication of the international search report:

8 March 2001

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.